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The high-mobility group–box transcription factor sex-determining region Y–box 2 (Sox2) is essential for the
maintenance of stem cells from early development to adult tissues. Sox2 can reprogram differentiated cells into
pluripotent cells in concert with other factors and is overexpressed in various cancers. In glioblastoma (GBM),
Sox2 is a marker of cancer stemlike cells (CSCs) in neurosphere cultures and is associated with the proneural
molecular subtype. Here, we report that Sox2 expression pattern in GBM tumors and patient-derived mouse
xenografts is not restricted to a small percentage of cells and is coexpressed with various lineage markers,
suggesting that its expression extends beyond CSCs to encompass more differentiated neoplastic cells across
molecular subtypes. Employing a CSC derived from a patient with GBM and isogenic differentiated cell model, we
show that Sox2 knockdown in the differentiated state abolished dedifferentiation and acquisition of CSC
phenotype. Furthermore, Sox2 deficiency specifically impaired the astrocytic component of a biphasic
gliosarcoma xenograft model while allowing the formation of tumors with sarcomatous phenotype. The
expression of genes associated with stem cells and malignancy were commonly downregulated in both CSCs and
serum-differentiated cells on Sox2 knockdown. Genes previously shown to be associated with pluripontency and
CSCs were only affected in the CSC state, whereas embryonic stem cell self-renewal genes and cytokine signaling
were downregulated, and the Wnt pathway activated in differentiated Sox2-deficient cells. Our results indicate that
Sox2 regulates the expression of key genes and pathways involved in GBM malignancy, in both cancer stemlike
and differentiated cells, and maintains plasticity for bidirectional conversion between the two states, with
significant clinical implications.
Neoplasia (2014) 16, 193–206.e25stem; CSC, cancer stem-like cell; DEG, differentially expressed gene; ESC, embryonic
intermediate filament protein; IHC, immunohistochemistry; NM, neurosphere media;
zone; SDC, serum differentiated cell; TCGA, the Cancer Genome Atlas; TMA, tissue
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or Center.
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In a variety of tumor types, a worse prognosis is associated with
increased plasticity, loss of differentiation makers, and induction of
stem cell phenotypes [1]. One key regulator of stemness is the high-
mobility group (HMG)–box transcription factor sex-determining
region Y (SRY)–box 2 (Sox2), essential in early embryonic
development [2]. Sox2 activity is critical for the maintenance of
mouse embryonic stem cells (ESCs) [3] and is associated with the
promoter region of 7% of protein-coding genes in human ESCs [4].
Sox2 activates and represses the expression of different gene sets in
various tissues during development through HMG-box domain-
mediated DNA binding. Cooperative binding of other transcription
factors contributes to target specificity [5]. Sox2 is highly expressed in
neural stem cells (NSC), neural progenitors, and immature astrocytes
in the subventricular zone (SVZ) of developing rodent brains and is
required for maintenance and identity of NSC in the adult mouse
brain [6]. Sox2 is re-expressed in astrocytes undergoing cell division in
the mouse neocortex in response to brain injury [7]. In the adult
human brain, Sox2 expression is restricted to regions with neurogenic
potential, such as the SVZ [8]. Outside of normal development, Sox2
is an essential component of the transcription factor cocktail for
reprogramming differentiated cells into iPS cells [9]. SOX2 gene is
amplified or otherwise overexpressed in several tumor types [5].
Transcriptional regulation by Sox2 is context dependent, and its
impact on malignancy is cancer-type specific. For example, Sox2
functions as an oncogene in lung and esophagus squamous cell
carcinomas [10], whereas in ovarian cancer, its expression is restricted
to cancer stemlike cells (CSCs) [11].
Glioblastoma (GBM), a WHO grade IV astrocytoma, is the most
aggressive primary central nervous system tumor. Sox2 transcript and
protein are upregulated in GBM tumors in relation to nontumor brain
tissues [12,13], gene amplification is observed in 4% of GBM tumors
profiled by The Cancer Genome Atlas (TCGA) [14], and promoter
hypomethylation occurs with high frequency [12]. Sox2 is a component
of the GBM proneural molecular subclass signature, along with other
regulators of neural stem/progenitor cell fate [15]. Notable phenotypic
plasticity of GBMs contributes to intratumor heterogeneity, encom-
passing cells in a range of developmental states, from CSCs to more
differentiated neoplastic cells. These various developmental states can be
partially captured ex vivo. Culturing GBM cells in serum-free medium
supplemented with epidermal growth factor (EGF) and fibroblast
growth factor (FGF) developed for NSCs allows the selection and
propagation of neurospheres, a population enriched in CSC, defined by
the ability to self-renew and differentiate into cells forming the bulk of
the tumor, phenocopying the parental tumor in mouse orthotopic
xenografts [16,17]. Sox2, ubiquitously expressed in GBM neurosphere
cell cultures [16–21], has been shown to function in the proliferation of
GBM CSC population and tumorigenicity [20]. Neurosphere cultures
derived from adult mouse SVZ also express Sox2, and differentiation
induced by FBS is accompanied by down-regulation of Sox2 mRNA
and protein [22]. Similarly, culturing dissociated GBM tumors in FBS-
containing media typically results in loss of the CSC phenotype and
impaired tumorigenicity associated with down-regulation of NSC
markers, including Sox2, and gain of more mature astrocytic markers
[16,17,19].
Here, we verify that the endogenous expression of Sox2 in GBM
biopsies and xenograft tumors is more widespread than expected for a
marker of CSCs, raising the question as to whether inGBM tumors Sox2performs distinct functions in differentiated and CSCs. Although few
long-term serum-culturedGBM cells can regain expression of Sox2 [23],
these cells accumulate genomic abnormalities leading to considerably
divergence from the original tumor [16].We have previously described a
patient-derived low -passage serum-differentiated cell (SDC) line, which,
contrary to typical GBM samples, retains Sox2 expression, alongwith the
ability to dedifferentiate into neurospheres in vitro and to phenocopy the
parental tumor in orthotopic xenografts [19]. These SDCs and CSCs
originating from the same tumor specimen [19] constitute an adequate
model to study Sox2 function in the two developmental states under an
isogenic background. Gliosarcoma (GS), aWHO histologic variant [24]
comprising approximately 1.8% to 2.8% of all GBMs, is characterized
by biphasic malignant glial and sarcomatous components, resulting from
mesenchymal metaplasia [25]. GSs are not distinguished from GBMs
regarding clinicalmanagement and large-scalemolecular profiling efforts,
such as the TCGA, and are assigned to multiple molecular subclasses
[26]. The availability of a GS model [19] presented an opportunity to
contrast Sox2 functions in the glial and mesenchymal compartments,
further highlighting its role in astrocytic tumorigenicity.
Materials and Methods
Tumor Samples and Cell Culture
Resected brain tumors were collected at Henry Ford Hospital
(Detroit, MI) with written consent from patients in accordance with
institutional guidelines and graded pathologically according to the
WHO criteria. GBM tumors were dissociated, as previously described
[27]. Dissociated cells were grown in Dulbecco's modified Eagle's
medium (DMEM) (Life Technologies) supplemented with 10% FBS
(HyClone) for traditional monolayer cultures or in neurosphere
medium (NM), composed of DMEM/F-12 supplemented with N2
(Gibco), 0.5 mg/ml BSA (Sigma), 25 μg/ml gentamicin (Gibco),
0.5% antibiotic/antimycotic (Invitrogen), 20 ng/ml basic fibroblast
growth factor, and 20 ng/ml EGF (Peprotech). Cells were maintained
in culture for up to passage 10 (low passage).
Immunohistochemistry
Immunohistochemistry was performed as described previously [19].
The following primary antibodies were used: anti-Sox2 (Cell Signaling
Technology), anti–glial fibrillary acidic protein (anti-GFAP) (Abcam),
anti-nestin (Millipore), anti-vimentin (Santa Cruz Biotechnology),
anti–α-smooth muscle actin (anti–α-SMA) (Abcam), and anti–major
histocompatibility complex I (anti-MHC I) (Abcam). Anti-Sox2
antibody specificity was verified by the absence of signal on Sox2
knockdown, as shown in Figure 4. Reticulin staining was performed
with a kit (DakoCytomation). Images were captured using Nikon
E800M microscope and DXM1200C digital camera. For immuno-
fluorescence, secondary antibodies conjugated to DyLight 488 and
DyLight 649 (Jackson ImmunoResearch Laboratories) were employed,
nuclei were stained with DAPI (Invitrogen), and images captured using
Nikon Eclipse 80i microscope equipped with epifluorescence.
Sox2 Knockdown and Ectopic Expression
Sox2 knockdown in low-passage 10% FBS cells was achieved by
oligonucleotides targeting human SOX2-coding or nonsilencing
control sequences cloned into BLOCK-iT Pol II miR RNAi
expression vectors (Life Technologies) before cell transfection with
Lipofectamine 2000 (Life Technologies). Sox2 knockdown in
neurospheres was achieved using GIPZ Lentiviral shRNAmir (clones
V3LHS_404430 and V3LHS_404432) and nonsilencing control
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expression was achieved by subcloning Sox2 cDNA from pCMV6-
XL5-NM_002106.2 (OriGene) into pcDNA 3.1 mammalian ex-
pression vector (Invitrogen), under control of constitutive CMV
promoter; the empty vector was used as control. Plasmid DNA
constructs were verified by DNA sequencing and stably transfected
into GBM monolayer cells using Lipofectamine 2000 (Invitrogen).
Neurosphere Formation Assay
Monolayer cells were harvested by trypsin treatment, washed three
times in serum-free DMEM/F-12 medium, and plated in NM in
regular tissue culture–treated flasks at a density of 10 cells per well.
Neurosphere formation was monitored for 2 weeks, and neurospheres
containing more than 32 cells were counted.
Cell Proliferation Assay
Cells were harvested and plated onto 96-well plates (500 cells per
well for 10% FBS cultures and 1000 cells per well for neurosphere
cultures). Cell viability was quantified for 7 days by intracellular ATP
level measurements using CellTiter-Glo Luminescent Cell Viability
Assay (Promega).
Xenograft Tumors
Following IACUC guidelines in an institutionally approved
animal use protocol, dissociated GBM cells were implanted into 8-
week-old female nude mice (NCRNU; Taconic Farms). Animals
were anesthetized with a mixture of ketamine and xylazine. The
injection site was manually drilled 2.5 mm to the right of the bregma
and 1 mm posterior to the coronal suture. Dissociated cells (3 × 105
per mouse) were injected at a depth of 3 mm using a Hamilton
syringe. Animals were monitored daily and killed on the first signs of
neurologic deficit or weight loss greater than 20%. Xenograft tissue
microarray (TMA) slides were obtained through participation in the
Ivy GBM consortium.
Proteasome Inhibition
Exponentially growing cells were plated at a density of 1 × 105
cells/ml in growth medium. After 24 hours, medium was replaced
with growth medium containing 10 μMMG132 (Sigma). Cells were
incubated for 4 to 24 hours at 37°C (5% CO2) before whole-cell
lysates were obtained.
Western Blot Analysis
Fifteen micrograms of total protein from whole-cell lysates were
denatured in sodium dodecyl sulfate–gel loading buffer and separated
by NuPAGE SDS-PAGE gel system (Life Technologies). Proteins
were electrophoretically transferred to PVDF membranes (Life
Technologies). Primary antibodies used were Sox2 (Chemicon) and
β-actin (Sigma-Aldrich). Immobilon Western Chemiluminescent
HRP substrate (Millipore) was used for detection.
Quantitative Real-Time Polymerase Chain Reaction Analysis
Total RNAwas extracted with RNeasyMini Kit (Qiagen), eluted in
RNase-free water, and stored at −80°C. cDNA was prepared from 1
μg of DNAse I–treated RNA using SuperScript III and oligo(dT)
(Invitrogen). Relative quantification of gene expression was performed
by real-time polymerase chain reaction (PCR) with SYBR Green and
ViiA 7 detection system (Applied Biosystems). β-Actin was used as
internal reference, and relative mRNA levels were quantified by the
2(−ΔΔCt) method. DNA oligo sequences are available on request.Global Gene Expression Analysis
RNA samples were analyzed by Illumina Human HT12v4.0
Expression BeadChip, at theWayne State University Applied Genomics
Technology Center. The gene expression image files obtained from the
Illumina iScan were uploaded to GenomeStudio (version 2010.3) using
theGene Expressionmodule. Illumina array data were normalized using
the rank invariant method, and the background was subtracted in
BeadStudio. Normalization artifacts of negative expression values were
set to a minimum null value. A single probe with the largest expression
range across the samples was selected for genes with multiple probes.
Fold change was calculated on the basis of the mean values for Sox2-
expressing cells (HF2303 parental and miRNAneg) and Sox2-deficient
cells (Sox2miR1 and Sox2miR2). Genes with mean Illumina intensity
levels lower than 20 for both groups were excluded. A stringent fold-
change cutoff of 3.5 was used to generate the differentially expressed
gene (DEG) lists. Global gene expression data files are available at GEO.
MetaCore (Thomson Reuters) and IPA (Ingenuity Systems) software
applications were used to further analyze the data sets. Microarray data
are available through GEO (GSE51441).
TCGA Data Analysis
Preprocessed level 2 Agilent Human Gene Expression Microarray
data were obtained from the TCGAData Portal (https://tcga-data.nci.
nih.gov/tcga/, July 2, 2012) for 517 GBM cases with no prior cancer
diagnoses. Analysis was conducted at probe level. Pearson correlation
coefficient between each of two Sox2 open reading frame probes
(A_23_P159606, A_24_0379969, r = 0.96) and all other probes was
conducted. A gene was considered to have consistent correlation if it
showed correlation of ρ N 0.4 (positive) or ρ b −0.4 (negative) for at
least 50% of its probes with either of the Sox2 probes. For
visualization, consistently correlated probes were z score transformed
and averaged to give a single value per gene. Hierarchical clustering of
the genes was performed using the Pearson correlation and complete
linkage. Molecular class was predicted from the metagene signatures
for the four classes. Analysis was performed using R Software.
Statistical Analysis
Results are represented as means ± SEM. Differences were
analyzed by unpaired two-tailed Student's t test or one-way analysis
of variance using Prism 5 (GraphPad Software). For Figures 4C and
W1C, Dunn multiple-comparison test was used. ANCOVA was
used for age-adjusted tests of means, and Cox regression was used for
survival analysis (R Software). P b .05 was considered significant.Results
Sox2 is Widely Expressed in GBM Tumors
Sox2 protein expression was assessed in newly diagnosed (n = 13)
and recurrent (n = 12) GBMs and in grade III anaplastic
oligodendroglioma (n = 9) and anaplastic astrocytomas (n = 5).
The percentage of Sox2-positive cells in GBM tumors ranged from
9% to 85% (Figure 1, A and B). Sox2 was similarly highly
expressed in the grade III gliomas (Figure 1B), in agreement with
previous reports [28,29]. Representative images are shown in
Figure 1C. The subclass assignment [15] was available for seven
GBM samples (Figure 1A). In the proneural samples, 64% and
85% of cells were positive for Sox2 (Figure 1A), consistent with
Sox2 being a component of the proneural subclass signature [15].
Sox2-positive cells ranged from 11.2% to 55.5% in the
Figure 1. Sox2 expression in GBM tumors. Sox2 expression in 25 GBMbiopsy specimens was assessed by immunohistochemistry. Sox2-
positive nuclei were quantified in four randomly selected ×400 optical fields per specimen. (A) Clinical information. (B) Scatterplot
represents the percentage of Sox2-positive cells for each specimen (mean ± SEM). Anaplastic oligodendroglioma (AO; n= 9), anaplastic
astrocytoma (AA; n = 5), and nontumor brain (n = 2) samples are included for reference. (C) Representative images show nuclear Sox2
expression in GBM biopsies; pseudopalisating necrosis (pp) and vessels (V) are indicated. (D) Graphical representation of Sox2 mRNA
expression in 23 paired primary (horizontal axis) and recurrent (vertical axis) gliomas. Square, WHO grade III primary and recurrent gliomas
(n= 3); circle, primary and recurrent (grade IV) GBMs (n= 16); triangle, primary grade III and recurrent GBM (n= 4). Patients grouped by
age (years): Green, b40; yellow, 40 to 60; red, N60.
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Sox2-positive cells in the recurrent GBM group relative to newly
diagnosed was observed (P = .0609; 95% confidence interval = −0.9%-
36.9%) (Figure 1B). When we adjusted for patient age at diagnosis
(Figure 1A), a significant decrease in Sox2 expression was observed in
the recurrent tumor group (21.7%, ANCOVA P = .0266; 95%confidence interval = 2.8%- 40.6%). To further investigate how Sox2
expression changes on recurrence, transcriptome data for 23 paired
primary and recurrent grade III and grade IV gliomas [30] were
analyzed. Sox2 expression obtained from two Affymetrix U133 probes
were not significantly different between primary and recurrent GBMs
(213721_at, P = .4618; 213722_at, P = .4293) (Figure 1D). Sox2
Figure 2. Sox2 expression in GBM neurospheres and orthotopic xenografts. (A) Sox2 expression in four sets of matched GBM biopsy,
cultured neurosphere cells, mouse xenograft, two newly diagnosed (HF2303 and HF2587), and two recurrent tumors (HF2609 and
HF2596). (B) Sox2-positive cells were quantified in TMA containing samples of xenograft tumors obtained from 51 GBM specimens
propagated in vitro as neurosphere cultures or subcutaneously in nude mouse flanks, before intracranial implant in nude mice. Xenograft
lines from subcutaneous and neurosphere propagation were ranked for Sox2 expression as high (N65% positive cells), moderate
(between 20% and 65% positive cells), and low (b20% cells). (C) Representative images for each xenograft category in B and normal
mouse brain (inner cortex). Scale, 20 μm.
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and for the grade III tumors (Figure 1D).
Together, these observations indicate that Sox2 expression is not
restricted to a small subpopulation of undifferentiated neoplastic cells,
suggesting that Sox2 could regulate different programs in CSCs and
more differentiated GBM cells.Sox2 Expression is Conserved in Patient-Derived GBM
Orthotopic Xenografts
To enrich for cells with CSC phenotype, neurosphere cultures
from two newly diagnosed GBMs (HF2303 and HF2587) and two
recurrent GBMs (HF2609 and HF2596) were implanted intracra-
nially in immunocompromised mice. Sox2 was expressed in 55% to
Figure 3. Sox2 is coexpressed with GFAP, nestin, and vimentin in neurosphere-derived GBM xenografts. (A) Coexpression of Sox2 (red)
with the IF proteins (green) nestin, GFAP, and vimentin in HF2303 and HF2596 GBMmouse xenografts. Nuclei counterstained with DAPI.
Scale, 40 μm. (B) Sox2 and nestin are expressed in xenografts formed from HF2303 neurospheres or low-passage 10% FBS cultures (P4)
and downregulated in higher passage (P20) 10% FBS serum cultures. Scale, 20 μm.
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expected, matched neurosphere cells were highly enriched in Sox2-
positive cells, and biopsy expression pattern was replicated in the
xenograft tumors (Figure 2A).
Sox2 expression was then evaluated in a TMA composed of
samples from 51 mouse orthotopic GBM xenografts, including 40
originating from patient tumors propagated subcutaneously and
11 from neurosphere cultures. As shown in Figure 2B, 36 (71%)
of the xenograft lines presented high percentage (N65%) of Sox2-
positive nuclei, whereas only 5 (9.8%) of the xenografts displayed
low (b20%) Sox2-positive nuclei. Representative images are
shown (Figure 2C). These results indicate that robust Sox2
protein expression observed for the majority of the patient-derived
orthotopic xenograft tumors is independent of the use of
neurosphere culture or subcutaneous tumors as the preimplanta-
tion propagation method.
The intermediate filament (IF) protein nestin is a direct target of
Sox2 regulation in neural stem and progenitor cells [31] and alsocommonly expressed in a large percentage of cells in GBM tumors
[19]. As expected, in neurosphere-derived GBM xenografts, Sox2
coexpressed with nestin (Figure 3A). Vimentin, the main IF protein
of mesenchymal cells, also expressed in neural stem and progenitor
cells, was coexpressed with Sox2 in the GBM xenografts
(Figure 3A). GFAP, a major IF of mature astrocytes, also expressed
in astrocytic progenitors, coexpressed with Sox2 (Figure 3A), as
previously reported [32]. Sox2 coexpression with IF proteins
markers of diverse lineages is in agreement with Sox2 not being
restricted to undifferentiated tumor cells, underlying the plasticity of
high-grade astrocytomas.
Whereas Sox2 is downregulated in the majority of GBM cells
exposed to 10% FBS, we have previously characterized a GBM
specimen, HF2303 (GS1), which retains Sox2 expression in low-
passage SDCs [19]. Here, we show that Sox2 expression in xenograft
tumors are consistent with the in vitro expression: Sox2-positive cells
are observed in xenografts derived from HF2303 neurosphere/CSCs
and low-passage SDCs (10% FBS P4) and not in higher passage
Figure 4. Sox2 knockdown prevents dedifferentiation of HF2303 GBM cells. (A) Sox2 and nestin mRNA levels in HF2303 cells (parental)
and cells transfected with miRNA constructs targeting Sox2 (Sox2miRNA1 and Sox2miRNA2) or nonsilencing miRNA (miRNAneg) was
evaluated by quantitative RT-PCR. HF2303 neurosphere cells (NP) were included for comparison. Results represent means ± SEM; n= 6.
(B) Sox2 protein expression in whole-cell lysates determined by Western blot analysis confirms Sox2 knockdown in Sox2miRNA1 and
Sox2miRNA2 lines. β-Actin was used as loading control. (C) The effect of Sox2 knockdown on dedifferentiation of HF2303 monolayers
into neurospheres. Cells were seeded at low density in 96-well plates and cultured in NM. Neurosphere formation was monitored and
quantified at day 12. Results represent means ± SEM, for n = 10 (*P b .05 and **P b .01), in relation to parental cells after Dunn multiple
comparison test. (D) Representative images contrast Sox2-expressing and Sox2-deficient cells in NM culture. Bar, 20 μm.
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follows the Sox2 pattern (Figure 3B).
Sox2 Function in Plasticity of Differentiated GBM Cells
To study Sox2 function in differentiated patient-derived GBM
cells, low-passage HF2303 SDCs were transfected with miRNA
constructs targeting the Sox2-coding region (Sox2miRNA1 and
Sox2miRNA2) or with a nonsilencing control (miRNAneg). Sox2
knockdown in HF2303_Sox2miRNA1 and HF2303_Sox2miRNA2
was verified by quantitative PCR (Figure 4A) and Western blot
analysis (Figure 4B). Knocking down Sox2 expression in HF2303
cells significantly decreased the level of nestin transcript, a direct
target of Sox2 (Figure 4A). Expression of Sox2 in isogenic HF2303
neurospheres (NP) are shown for comparison (Figure 4, A and B).
We have previously demonstrated that HF2303 SDCs not only retain
Sox2 expression but also the ability to dedifferentiate, forming
neurospheres in a clonogenic assay [19]. Sox2 knockdown signifi-
cantly impaired neurosphere formation in NM (Figure 4, C and D),
whereas no effect in proliferation was observed (Figure W1).
Sox2 Expression is not Sufficient to Restore Plasticity and
Tumorigenicity to Serum-Cultured Primary GBM Cells
We have previously described neurosphere/CSCs and SDCs from
another GBM specimen (HF2414/GBM2) [19], demonstrating thatthe CSCs express Sox2 and are tumorigenic, whereas the low-passage
SDCs lose Sox2 expression, along with the ability to dedifferentiate
in vitro, and to form tumors [19], typical observations for GBM
SDCs [16]. To determine whether Sox2 ectopic expression was
sufficient to restore plasticity and tumorigenicity to HF2414 SDCs,
cells were stably transfected with Sox2 cDNA construct. Detectable
levels of Sox2 protein expression were only attained in clones
expressing very high levels of Sox2 transcript (HF2414-hSox2) in
relation to clones expressing the empty vector (HF2414 V)
(Figure 5, A and B). Endogenous Sox2 expression was negligible
in HF2414 V cells and was not upregulated when cells were
cultured in serum-free NM for 48 hours (Figure 5, A and B).
Nestin mRNA was upregulated on ectopic Sox2 expression and
further upregulated when the cells were transferred to NM
(Figure 5A). The discrepancy between mRNA and protein levels
(Figure 5, A and B) suggests that the posttranslational regulation of
Sox2 expression is affected by culture conditions, because increased
protein levels were observed when HF2414-hSox2 was transferred
from 10% FBS to NM for 48 hours (Figure 5B), which was not
mediated by an increase in mRNA expression (Figure 5A).
Treatment with proteasome inhibitor MG132 (10 μM) increased
Sox2 protein levels in HF2414-hSox2 cells (Figure 5B). Although
predicted ubiquitin-binding sites exist in Sox2 (http://ubpred.org),
we found no evidence of direct ubiquitination of Sox2 (not shown).
Figure 5. Sox2 ectopic expression in low-passage primary GBM monolayer line HF2414. HF2414 cells constitutively expressing Sox2
(HF2414-hSox2) or the empty vector (HF2414-V) were maintained in 10% FBS culture or transferred to NM for 48 hours. (A) Sox2 and
nestin mRNA levels were determined by quantitative RT-PCR. Results represent means ± SEM, for n = 6. (B) Sox2 protein expression in
whole-cell lysates was determined byWestern blot analysis. Sox2 protein was detected in the HF2414-hSox2 grown in serum, and protein
expression was increased when cells were transferred to NM or when proteasome inhibitor MG132 was added to the 10% FBS serum
containing medium in a time-dependent manner. No Sox2 protein was observed in the HF2414-V cell line under the same culture
conditions. (C) Cell proliferation in 10% FBSmediummeasured by CellTiterGlo was decreased for HF2414-hSox2 cells relative to HF2414-
V cells. Mean ± SE (n = 10) is shown in the graph (*P b .05). (D) When the cells were plated in low density in NM, no neurospheres
formed, and there was a reduction in cell viability for 7 days, significantly more accentuated for HF2414-V. Mean ± SE (n= 10) is shown in
the graph (*P b .05).
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the same conditions (Figure 5B), in agreement with irreversible loss
of endogenous Sox2 commonly observed for GBM SDCs. Ectopic
expression of Sox2 had a negative effect in HF2414 cell
proliferation in 10% FBS (Figure 5C) and was not sufficient to
induce CSC phenotype or restore tumorigenicity to HF2414 SDCs
(not shown) but led to significant increase in cell viability in NM
(Figure 5D).
Sox2 Knockdown Alters Tumor Formation and Abolishes the
Astrocytic Phenotype in Biphasic GS Tumor
We have previously demonstrated that CSCs and low-passage
SDCs from HF2303 GS tumor retain the intrinsic ability to generate
the biphasic glial and sarcomatous tumor in orthotopic xenografts
[19]. Sox2 deficiency in HF2303 SDCs reduced tumorigenicity, as
observed by a 50% decrease intake rate relative to the control group
(miRNAneg) (Figure 6A). GBM xenograft tumors were labeled with a
human-specific marker (MHC I, Figure 6B). Distinct GFAP and
reticulin-positive regions were observed in the Sox2-positive tumors
(Figure 6C), as previously demonstrated [19]. Sox2 was expressed in
both the glial and sarcomatous compartments of the xenograft
tumors, although fewer positive cells were observed in the
sarcomatous compartment (Figure 6C). No Sox2-positive tumor
cells or GFAP expression was observed in the Sox2miRNA xenografts,and the entire tumor consisted of the sarcomatous component, as
evidenced by the reticulin staining (Figure 6C). Murine and human
Sox2 proteins share 99.4% amino acid identity, leading to cross-
species antibody labeling. Because Sox2-positive cells exist in the
adult mouse brain (e.g., Figure 2C), colabeling of the human marker
and Sox2 was used to distinguish between Sox2 expression in the
human tumor (Figure 6, C and D, green arrowheads) and in mouse
host brain tissue (Figure 6, C and D, black arrows), demonstrating
that Sox2 protein was not detected in neoplastic cells of xenograft
tumors from Sox2-deficient HF2303 cells. GS sarcomatous com-
partment can display diverse mesenchymal phenotypes. HF2303
mesenchymal component in the biopsy and xenografts is positive for
α-SMA, a marker of myogenic lineage [19]. Sox2-deficient xenografts
expressed α-SMA throughout the tumor (Figure 6E), further
verifying the sarcomatous nature of the tumors.
Sox2 Regulates the Expression of Distinct Sets of Genes in
Differentiated and CSC States
To better understand transcriptional regulation by Sox2 in
differentiated GBM cells, genes differentially expressed between
Sox2-positive HF2303 low-passage SDCs (parental and
HF2303miRneg) and cells where Sox2 has been knocked down
(HF2303_Sox2miRNA1 and HF2303_Sox2miRNA2) were derived
from genome-wide transcriptome data (Illumina HT12v4.0). To
Figure 6. Sox2 loss affects the astrocytic compartment of GS. HF2303-parental, HF2303-mirRNAneg, HF2303-Sox2miRNA1, and HF2303-
Sox2miRNA2 cells were implanted intracranially in immunocompromised mice (n = 20-23).( A) Percentage of animals in each group that
succumbed to tumor burden within 150 days post-implant. (B) Representative images of the xenograft tumors labeled with the human cell
marker MHC I. Scale, 300 μm. (C) Sequential coronal sections of FFPE xenograft brains were labeled with anti-Sox2 antibody recognizing
both human and mouse (h,m) proteins, with human-specific antibodies against nestin, GFAP, andMHC I, and stained with reticulin. GFAP
and reticulin are markers of the glial (G) and sarcomatous (S) phases of the biphasic GS tumors. Representative images for Sox2-positive
and Sox2-negative tumors are shown. Scale, 40 μm. (D) Colabeling of the human marker MHC I (red) and Sox2 (brown). Human cells
expressing Sox2 in the tumor (T) (green arrowhead) and mouse brain cells expressing Sox2 (black arrow) are shown for representative
images of Sox2-expressing and Sox2-deficient xenograft tumors. Scale, 20 μm. (E) α-SMA is expressed throughout the tumor from Sox2-
deficient HF2303 cells.
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lentivirus-shRNA–mediated Sox2 knockdown in HF2303 neuro-
spheres was attained (Figure W1), and differential gene expression
between Sox2-positive (parental and NSV-shRNA) and Sox2-
deficient (Sox2shRNA1 and Sox2shRNA2) was similarly analyzed.
Applying a 3.5-fold change cutoff (1.8 log2), Sox2 knockdown
affected the expression of 736 genes in SDCs (453 downregulated and
283 upregulated) and 799 genes in CSCs (341 downregulated and
458 upregulated) (Figure 7A). Table W1 contains the complete DEG
lists. Only 62 transcripts were commonly regulated in SDCs and
CSCs, whereas 35 presented opposite change in expression between
the two groups (Figure 7A and Table W1). Overlap with Sox2
binding to cis-regulatory sequences was observed for 25.1% and
15.1% of DEGs in SDC and CSC, respectively (Table W1),
suggesting a direct regulation by Sox2 for this subset. A total of 94
DEGs overlapped with GBMmolecular subclass signature genes [15].
In Sox2-deficient cells, proneural and classic signature genes were
notably downregulated in SDCs and to a lesser extent in CSCs,
whereas mesenchymal signature genes were upregulated in both
groups (Figure 7B and Table W1).
To compare the above results with genes correlated with Sox2
expression in tumor tissues, gene expression data for 517 GBMs in
TCGA were analyzed to identify 56 and 17 genes presenting positive
and negative correlation with Sox2 expression, respectively (TableW2
and Figure 7C). Significantly, 28.6% of the positively correlated genes
overlapped with the DEGs inHF2303: 3 genes in both CSC and SDC
states, 1 in CSCs, and the remaining 12 in the SDC state (Table W2
and Figure 7C), suggesting that genes correlated with Sox2 expression
in the tumors are better represented in SDCs than in CSCs.
Top canonical signaling pathways and top GO network pathways
representing the DEGs on Sox2 knockdown in CSCs and SDCs were
identified using IPA andGeneGO/MetaCore, respectively (Figure 7D).
Genes altered in SDCs were more connected in the pathway analyses
than those in CSCs. Chemokine signaling was significantly affected by
Sox2 knockdown in HF2303 cells. IL-8 expression was downregulated
in both CSC and SDCs (Figure 7E), and DEG genes were enriched in
IL-8 signaling components, especially in SDCs (Figure 7D). Chemo-
kine (C-X-C motif) receptor 4 (CXCR4), a chemokine receptor
involved in glioma cell invasion, was downregulated in SDC
(Figure 7E), affecting CXCR4 signaling (Figure 7D).
Wnt receptors Frizzled homolog 2, as well as ligands Wnt2, Wnt3,
and Wnt5B, were upregulated, whereas low-density lipoprotein–
related protein 1, a negative regulator, and lymphoid enhancer-
binding factor 1, a transcription mediator of Wnt signaling, wereFigure 7. Sox2 regulates distinct gene sets in GBM stem and dif
differentially expressed on Sox2 knockdown in HF2303 SDC and C
expression; up arrow, upregulated, negative correlation with Sox2 exp
that overlap with the subclass signature. On Sox2 knockdown, proneu
and modestly in CSC [positive (+) correlation], whereas mesenchyma
both groups. The pattern of expression of neural (NL) signature genes
TCGAGBM data set was significantly correlated with 73 genes. The 51
and colored by their molecular class (red, mesenchymal; blue, classic
converted to z scores, averaged across probes for each gene, and t
standardized intensity with red high and green low. Select genes posit
downregulated on Sox2 knockdown in HF2303 SDC and CSC are ind
Sox2 (#) or part of subclass signatures are indicated. (D) Signaling pat
pathways (IPA) and top GO networks (GeneGo/MetaCore). (E) Graph
HF2303 cells, represented as log2 fold change. (F) Schematic repr
regulation in stemlike and differentiated GBM cells.downregulated (Figure 7E). Up-regulation of Wnt target genes con-
nective tissue growth factor, cyclin D1, and Dickkopf homolog 1
(Figure 7E) provide additional evidence that Wnt signaling is
activated on Sox2 knockdown in SDCs (Figure 7D). Genes involved
in GBM, insulin-like growth factor 1 (IGF-1), protein kinase A, and ρ
GTPase signaling were also significantly enriched in the SDC data set
(Figure 7D).The top GO networks indicate that Sox2 loss in SDCs
results in down-regulation of genes involved in central nervous system
development and up-regulation of genes involved in cell-cell signaling
(Figure 7D). Sox2 knockdown in CSCs led to up-regulation of genes
associated with response to retinoic acid (Figure7D). Conversely,
retinoic acid decreased Sox2 expression in GBM neurosphere
cells [33].
On Sox2 knockdown, α-SMA (actin, α 2) was upregulated in
CSCs (Figure 7E) and in SDCs (by 3.2-fold, not shown), in
agreement with the widespread expression of α-SMA observed for the
Sox2-deficient GS xenografts (Figure 6E) and with the lower
expression of Sox2 in the sarcomatous phase observed for Sox2-
positive tumors (Figure 6C). Genes commonly altered on Sox2
knockdown in both SDC and CSC states are enriched in ESC genes,
including Sox21 and Tweety 1, both positively correlated with Sox2
expression in the TCGA data set (Figure 7C), CCR4-NOT
transcription complex subunit 3 (CNOT3), fatty acid binding protein
7 (FABP7), and podoplanin (PDPN) (Figure 7E). Several genes
associated with stem/progenitor cells were exclusively downregulated
in SDCs: Brain and acute leukemia, cytoplasmic (BAALC), smoothened
homolog (SMO), Sal-like 1 (SALL1), nestin (NES), and platelet-derived
growth factor receptor α (PDGFRα) (Figure 7E), in agreement with
enrichment of ESC self-renewal signaling genes in SDCs (Figure 7D).
Genes downregulated in Sox2-deficient CSCs include n-Myc
(MYCN), Krüppel-like factor 4 (KLF4), integrin-α6 (ITGA6), and
aldehyde dehydrogenase 1 family, member A1 (ALDH1A1)
(Figure 7E). A schematic model summarizing the main findings
reported here is shown in Figure 7F.
Discussion
Sox2 is considered a CSC marker for GBMs due in part to its
ubiquitous expression in tumorigenic neurosphere cultures [16,18–
21] and analogous role in the determination of NSC identity [6].
However, Sox2 expression in 9% to 85% of GBM tumor cells
reported here, and comparable to previous reports [13,28,29],
indicates that Sox2 expression encompasses more differentiated
neoplastic cells as well. To investigate Sox2 function in GBM
differentiated cells, we used a rare low-passage SDC line derived fromferentiated cells. (A) Venn diagram shows the overlap of genes
SC. Down arrow, downregulated, positive correlation with Sox2
ression. (B) Genes differentially regulated in HF2303 CSC and SDC
ral (PN) and classic (CL) signature genes are downregulated in SDC
l (MES) signature genes are upregulated [negative (−) correlation] in
did not correlate with Sox2 expression. (C) Sox2 expression in the
7 GBM cases are ordered according to the level of Sox2 expression
; green, neural; purple, proneural). The mRNA expression data were
hen ordered by hierarchical clustering. The heat map displays the
ively correlated with Sox2 expression are noted. Overlap with genes
icated by (*) and (**), respectively. Genes that are direct targets of
hway analysis of the DEGs in CSC and SDC shows the top signaling
with selected DEGs between Sox2-expressing and Sox2-deficient
esentation of Sox2 role in GBM cell plasticity and transcriptional
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dedifferentitation and tumorigenic potential [19]. Tissue culture
manipulation, such as the use of FBS to induce astrocytic
differentiation, has provided insights into the differentiation potential
of both NSCs [34] and GBMCSCs [35]. High-passage 10% FBS cell
cultures incur accumulation of genomic abnormalities leading to a
deviation of the GBM phenotype, even when these cells are
tumorigenic [16,36]. Low-passage 10% FBS cultures commonly
present down-regulation of NSC markers, including Sox2, and loss of
tumorigenic potential [16,19], thus only partially representing the
molecular profile of differentiated cells in the tumor.
Despite the caveats for the use of FBS as differentiation stimulus for
GBM cells, we report a significant overlap of genes affected by Sox2
knockdown in SDCs and genes highly correlated with Sox2 expression
in GBM tumor tissue profiled by TCGA. Several genes associated with
ESCs and cancer were commonly downregulated in both CSCs and
SDCs on Sox2 knockdown: Sox21, a known Sox2 target in GBMs
[32] andmediator of Sox2 activity in several cell types, including colon
cancer [37]; Tweety 1, a proneural subclass signature member and ER
protein also required in embryonic and brain development [38];
CNOT3, involved in ESC self-renewal [39]; FABP7, expressed in
radial glia cells and associated with GBM malignancy and cell
migration [40]; and PDPN, involved in tumor invasion [41]. Several
other genes associated with stem and progenitor cells were exclusively
downregulated in Sox2-deficient SDCs: BAALC, restricted to
neuroectoderm tissues and overexpressed in acute leukemia and
GBM [42]; Shh receptor SMO; SALL1, a zinc finger transcription
factor activator of NANOG in ESCs [43]; and the known Sox2 targets
nestin and PDGFRα [32]. Wnt pathway activation on Sox2
knockdown, reported here for GBM SDCs, has been observed in
osteosarcomas [44]. Interestingly, Wnt activation has been shown to
induce differentiation of GBM CSCs [45]. Activation of CXCR4
expression by Sox2 is in agreement with previous reports [21].
Paracrine IL-8 in perivascular niches has been recently shown to
regulate GBM CSCs [46], and here, we report for the first time a
strong correlation of Sox2 expression in GBM SDCs and CSCs with
IL-8 expression and signaling. Activation of IGF-1 signaling on Sox2
knockdown in SDCs may explain the reported sensitivity of Sox2-
deficient GBM cells to the IGF-1R inhibition [21]. Loss of Sox2 led to
down-regulation of several genes exclusively in CSCs, in particular
transcription factors that act in concert with Sox2 to reprogram
somatic cells into iPS cells (MYCN and KLF4) [47] and other genes
previously associated with CSCs (ALDH1A1 and ITGA6) [48].
Sox2 is part of the gene signature for the GBM proneural molecular
subclass [15]. Here, we show that Sox2 was correlated with the
expression of both proneural and classic signature genes in the TCGA
data set and in vitro functional studies. Furthermore, loss of Sox2
resulted in up-regulation of mesenchymal signature genes in vitro. No
significant difference in Sox2 expression between recurrent and newly
diagnosed GBMs was observed at protein level in this study or at
transcript level in paired samples [30]. Mechanisms leading to the up-
regulation of Sox2 in GBM tumors include gene amplification
[12,14,18], promoter hypomethylation [12], translational regulation
[49], and activated signaling pathways [50]. Posttranslational
regulation of Sox2 level by proteolysis has been previously observed
in committed neuronal precursor cells [7]. Sox2 protein stabilization
by MG132 treatment reported here has also been observed in mouse
ESCs [51], and although the mechanism remains to be determined, it
has possible implications for the clinical use of proteasome inhibitors.Sox2 expression is retained in patient-derived orthotopic xenografts
generated from neurosphere cells, in agreement with previous studies
[52], and also from subcutaneously propagated tumors. It has been
previously reported that Sox2 loss in GBM neurospheres impairs
tumorigenicity [20,50]. Here, we show that Sox2 knockdown in GBM
SDCs abolished dedifferentiation and acquisition of CSC phenotype in
vitro and decreased tumorigenicity. Ectopic Sox2 expression was not
sufficient to reprogram typical Sox2-deficient low-passage GBM SDCs
to regain plasticity and tumorigenicity, possibly due to insufficient levels
of required cofactors, similar to what has been observed in a high-passage
GBM cell line [12]. Furthermore, we show that in the context of
biphasic GSs, Sox2 specifically regulates the glial component, which
displays histologic features typical of GBMs, whereas the loss of Sox2 did
not affect the sarcomatous compartment, identified by reticulin staining
of the dense extracellular matrix and composed of GFAP-negative
spindle cells [24]. These findings have potential clinical implications in
that any intervention aimed at decreasing Sox2 activity or downstream
pathways in GS could favor metaplastic sarcomatous tumor growth.
We propose that Sox2 function in GBMs resemble not only its role
in ESC and NSC identity, maintenance, and fate but also its function
in committed progenitors and proliferating astrocytes [7]. As
evidences continue to point to a “plastic CSC model” [53] for
GBMs, our results indicate that Sox2 may be central to the
maintenance of developmental plasticity during glial tumor progres-
sion, regulating dedifferentiation and acquisition of CSC properties.
Furthermore, Sox2 regulates gene expression and signaling critical to
malignancy in more differentiated cells.
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es. Cells were seeded at low density in 96-well players and cultured
using CellTiter-Glo Luminescent Cell Viability Assay (Promega). (E)
cells in NM. (F) The effect of Sox2 knockdown on proliferation of
ers and cultured in FBS. Viability was measured on days 1, 3, and 7.
Table W1. DEGs in HF2303 GBM Cells on Sox2 Knockdown.
SDC
Description Symbol Fold Change
(Log2)
Sox2 Target
(Ref)
Subclass
Signature
ATP-binding cassette, subfamily A (ABC1), member 8 ABCA8 −4.3
ATP-binding cassette, subfamily A (ABC1), member 9 ABCA9 −1.9
ATP-binding cassette, subfamily B (MDR/TAP), member 9 ABCB9 −1.8
ATP-binding cassette, subfamily D (ALD), member 1 ABCD1 −1.9
Abhydrolase domain containing 11 ABHD11 −2.9
Abhydrolase domain containing 3 ABHD3 −2.0
ACN9 homolog (Saccharomyces cerevisiae) ACN9 −2.3
Acyl-CoA synthetase bubblegum family member 1 ACSBG1 −5.8 CL
Acyl-CoA synthetase family member 2 ACSF2 −1.8
ADAM metallopeptidase with thrombospondin type 1 motif, 1 ADAMTS1 −2.2
Adenosine A1 receptor ADORA1 −2.1
AE binding protein 1 AEBP1 −2.3
Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) AGT −5.6
Adenosylhomocysteinase-like 2 AHCYL2 −3.0
Allograft inflammatory factor 1-like AIF1L −3.9
AKNA domain containing 1 AKNAD1 −2.2
Aldo-keto reductase family 1 member 15 (ALD2) AKR1B15 −3.1
V-akt murine thymoma viral oncogene homolog 2 AKT2 −3.0 CL
Aldehyde dehydrogenase 1 family, member A1 ALDH1A1 −7.7 (1)
Anaplastic lymphoma kinase (Ki-1) ALK −4.2 (1)
Ankyrin 2, neuronal ANK2 −4.1
Ankyrin repeat domain 20 family, member A4 ANKRD20A4 −3.8
Ankyrin repeat domain 9 ANKRD9 −1.9
Ankyrin repeat and sterile α motif domain containing 1B ANKS1B −2.3 (1) NL
Adaptor-related protein complex 2, α 1 subunit AP2A1 −2.1 (1)
Adenomatosis polyposis coli down-regulated 1 APCDD1 −2.6
Amyloid β (A4) precursor-like protein 1 APLP1 −2.2
Arf-GAP with ρ-GAP domain, ANK repeat and PH domain-containing protein 3 ARAP3 −1.9
ADP-ribosylation factor-like 4A ARL4A −2.3 (1)
Aryl-hydrocarbon receptor nuclear translocator 2 ARNT2 −3.2
Acetylserotonin O-methyltransferase-like ASMTL −1.8
ATPase, class V, type 10B ATP10B −2.5
Β-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) B3GAT1 −2.8 (1)
Brain and acute leukemia, cytoplasmic BAALC −3.3
Brain-specific angiogenesis inhibitor 3 BAI3 −3.3 (1) PN
Bardet-Biedl syndrome 2 BBS2 −1.9
Butyrylcholinesterase BCHE −4.0 (1)
Brain expressed, X-linked 1 BEX1 −3.1 PN
Bloom syndrome BLM −2.2 (1) CL
Bone marrow stromal cell antigen 2 BST2 −2.5
BTB (POZ) domain containing 11 BTBD11 −3.7 (1)
BTG family, member 2 BTG2 −3.0
Chromosome 15 open reading frame 59 C15orf59 −2.6
Chromosome 18 open reading frame 56 C18orf56 −3.8
Chromosome 1 open reading frame 54 C1orf54 −3.2 MES
Chromosome 1 open reading frame 61 C1orf61 −3.5 (1)
Chromosome 2 open reading frame 40 C2orf40 −2.1
Chromosome 2 open reading frame 76 C2orf76 −1.9
Chromosome 3 open reading frame 70 C3orf70 −4.9
Chromosome 7 open reading frame 43 C7orf43 −2.1
Chromosome 8 open reading frame 4 C8orf4 −3.4 (1)
Carbonic anhydrase II CA2 −5.3
Calcium channel, voltage-dependent, P/Q type, α 1A subunit CACNA1A −2.1 (1)
Calcium channel, voltage-dependent, β 2 subunit CACNB2 −2.1 (1)
Cell adhesion molecule 4 CADM4 −3.7
Ca2+−dependent activator protein for secretion 2 CADPS2 −2.5 (1)
Calcitonin receptor-like CALCRL −4.9 (1)
Calcium/calmodulin-dependent protein kinase (CaM kinase) II β CAMK2B −2.0 (1) CL
Calcium/calmodulin-dependent protein kinase II inhibitor 1 CAMK2N1 −2.7 (1)
Caspase recruitment domain family, member 8 CARD8 −2.7
Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, β, convertase) CASP1 −2.1 MES
Coiled-coil domain containing 74B CCDC74B −2.0
CD276 molecule CD276 −1.8
CD83 molecule CD83 −2.4 (1)
Cat eye syndrome chromosome region, candidate 1 CECR1 −4.2
Cell cycle exit and neuronal differentiation 1 CEND1 −3.4
Centrosomal protein 112kDa (CCDC46) CEP112 −2.0
Complement factor I CFI −2.9
Coiled-coil-helix-coiled-coil-helix domain containing protein 10, mitochondrial CHCHD10 −2.2
Cell adhesion molecule with homology to L1CAM (close homolog of L1) CHL1 −7.9 (1)
Choline phosphotransferase 1 CHPT1 −1.9
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Cholinergic receptor, nicotinic, α 9 CHRNA9 −2.8
Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 CHST1 −3.8
Carbohydrate sulfotransferase 10 CHST10 −2.5
Carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 CHST2 −2.8
Creatine kinase, brain CKB −1.9
Chloride channel 2 CLCN2 −2.7
Claudin 23 CLDN23 −2.6
CAP-GLY domain containing linker protein 2 CLIP2 −2.8 CL
Calsyntenin 2 CLSTN2 −2.5 (1)
CCR4-NOT transcription complex, subunit 3 CNOT3 −2.2
Canopy 4 homolog (zebrafish) CNPY4 −2.5
Coagulation factor C homolog, cochlin (Limulus polyphemus) COCH −2.1
Collagen, type XXII, α 1 COL22A1 −2.2 (1)
Collagen, type IV, α 5 (Alport syndrome) COL4A5 −2.3 (1)
Collagen, type IV, α 6 COL4A6 −4.8 (1)
Collagen, type IX, α 2 COL9A2 −2.2
Coronin, actin binding protein, 2B CORO2B −2.0 (1)
DNA-directed RNA polymerase III subunint RPC9 CRCP −1.9
Cysteine-rich protein 1 (intestinal) CRIP1 −3.0
Crystallin, γ S CRYGS −4.5
Cysteine and glycine-rich protein 2 CSRP2 −2.9
Chemokine (C-X3-C motif) ligand 1 CX3CL1 −2.4 (1)
Coxsackie virus and adenovirus receptor CXADR −2.3 (1)
Chemokine (C-X-C motif) ligand 14 CXCL14 −3.3
Chemokine (C-X-C motif) receptor 4 CXCR4 −2.4 (1) (3)
Cytochrome b5 reductase 2 CYB5R2 −3.5
Cytochrome c, somatic CYCS −1.9 (1)
Cytochrome P450, family 51, subfamily A, polypeptide 1 CYP51A1 −2.2
Dysbindin (dystrobrevin binding protein 1) domain containing 1 DBNDD1 −2.2
Dehydrogenase/reductase (SDR family) member 3 DHRS3 −2.2
DIRAS family, GTP-binding RAS-like 3 DIRAS3 −2.1
Discs, large homolog 3 (neuroendocrine-dlg, Drosophila) DLG3 −2.6
DLGAP1 antisense RNA 2 DLGAP1-AS2 −2.3
Distal-less homeobox 1 DLX1 −1.8
DNA-directed RNA polymerase III subunit RPC9 DNAJC30 −1.8
Dynamin 3 DNM3 −1.8 (1) PN
Dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2) DPP4 −2.1
Dorsal inhibitory axon guidance protein DRAXIN −4.0
Dystrobrevin, α DTNA −2.8 (1)
Dual specificity phosphatase 4 DUSP4 −2.8
Dual specificity phosphatase 6 DUSP6 −2.9
Endothelin receptor type B EDNRB −5.0
Endonuclease/exonuclease/phosphatase family domain containing 1 EEPD1 −1.8
Eukaryotic translation initiation factor 1A, Y-linked EIF1AY −4.2
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) ELAVL1 −2.7
Engulfment and cell motility 1 ELMO1 −3.5 (1)
Elastin (supravalvular aortic stenosis, Williams-Beuren syndrome) ELN −2.8
Elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2 ELOVL2 −8.3 (1) CL
ER membrane protein complex subunit 10 EMC10 −1.9
Energy homeostasis associated ENHO −2.1
Enolase superfamily member 1 ENOSF1 −1.8
Epoxide hydrolase 4 EPHX4 −3.1
Estrogen-related receptor γ ESRRG −2.3 (1)
Fatty acid binding protein 5 (psoriasis-associated) FABP5 −1.9 (1)
Fatty acid binding protein 7, brain FABP7 −10.4
Family with sequence similarity 196, member A FAM196A −3.7
Family with sequence similarity 212, member B FAM212B −2.4
Family with sequence similarity 43, member A FAM43A −4.7 (1)
Family with sequence similarity 69, member C FAM69C −5.8
Family with sequence similarity 84, member B FAM84B −2.6 (1)
Fasciculation and elongation protein ζ 1 (zygin I) FEZ1 −2.4
Fin bud initiation factor FIBIN −4.9
Hypothetical gene supported by AK094963 FLJ37644 −2.5
Fibronectin leucine rich transmembrane protein 3 FLRT3 −3.3
V-fos FBJ murine osteosarcoma viral oncogene homolog FOS −2.2
Forkhead box S1 FOXS1 −2.1
FERM and PDZ domain containing 3 FRMPD3 −3.2
Frizzled homolog 3 (Drosophila) FZD3 −3.4 CL
Γ-aminobutyric acid (GABA) A receptor, β 1 GABRB1 −2.9
Galactose-3-O-sulfotransferase 4 GAL3ST4 −2.0
UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1 (GalNAc-T1) GALNT1 −1.8 (1)
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UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 4 (GalNAc-T4) GALNT4 −1.8 CL
UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-like 1 GALNTL1 −4.5
Growth associated protein 43 GAP43 −5.2 (1)
Growth arrest-specific 8 GAS8 −3.0
Gap junction protein, β 2, 26kDa GJB2 −2.5
Glycosyltransferase 25 domain containing 2 GLT25D2 −2.0
Guanine nucleotide binding protein (G protein), α inhibiting activity polypeptide 1 GNAI1 −2.1 (1) NL
Guanine nucleotide binding protein (G protein), γ 11 GNG11 −3.2 (1)
Guanine nucleotide binding protein (G protein), γ 2 GNG2 −5.2 (1)
Guanine nucleotide binding protein (G protein), γ 7 GNG7 −2.1 CL
Glycoprotein M6A GPM6A −4.8 PN
Glycoprotein M6B GPM6B −3.7
G protein–coupled receptor 162 GPR162 −2.0
G protein–coupled receptor 56 GPR56 −3.2
Growth factor receptor-bound protein 10 GRB10 −1.9
Hyaluronan synthase 3 HAS3 −4.9
Histone deacetylase 4 HDAC4 −3.0 (1)
Hepatocyte cell adhesion molecule HEPACAM −3.9
Hairy/enhancer-of-split related with YRPW motif 1 HEY1 −2.6 (1)
HHIP antisense RNA 1 HHIP-AS1 −4.8
Huntingtin interacting protein 1 HIP1 −3.0
High-mobility group AT-hook 1 HMGA1 −1.8
Homer homolog 1 (Drosophila) HOMER1 −6.5
Hippocalcin-like 1 HPCAL1 −2.2 (1)
Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 HS3ST1 −2.7 (1)
Heat shock 70kDa protein 6 (HSP70B′) HSPA6 −2.1
Heat shock protein, α-crystallin-related, B6 HSPB6 −4.1
Indoleamine 2,3-dioxygenase 1 IDO1 −2.8
Iduronate 2-sulfatase (Hunter syndrome) IDS −1.9
Intraflagellar transport 57 homolog (Chlamydomonas) IFT57 −2.4
Intraflagellar transport 81 homolog (Chlamydomonas) IFT81 −1.8
Insulin-like growth factor 2 mRNA binding protein 3 IGF2BP3 −5.7
Insulin-like growth factor binding protein 2, 36kDa IGFBP2 −6.0
Insulin-like growth factor binding protein 3 IGFBP3 −1.9 (1)
Insulin-like growth factor binding protein 5 IGFBP5 −2.0
Immunoglobulin superfamily, member 1 IGSF1 −2.0
Immunoglobulin superfamily, member 5 IGSF5 −2.1
Interleukin 17 receptor B IL17RB −2.0
Interleukin-1 receptor accessory protein-like 1 IL1RAPL1 −8.5 PN
Interleukin-27 receptor, α IL27RA −2.2 (1)
Interleukin-33 IL33 −5.0
Interleukin-8 IL8 −2.4 (1)
Inositol 1,4,5-triphosphate receptor, type 2 ITPR2 −2.4 (1)
Potassium voltage-gated channel, subfamily F, member 1 KCNF1 −2.0 (1) CL
Kv channel interacting protein 4 KCNIP4 −2.5 (1)
Potassium inwardly-rectifying channel, subfamily J, member 2 KCNJ2 −2.0 (1)
Potassium channel, subfamily K, member 12 KCNK12 −2.8
Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 KCNN4 −2.5
Potassium channel tetramerisation domain containing 12 KCTD12 −2.4
Potassium channel tetramerisation domain containing 13 KCTD13 −2.6
Potassium channel tetramerisation domain containing 17 KCTD17 −2.2
Lysine (K)-specific demethylase 5D KDM5D −2.8
KIAA0408 KIAA0408 −2.3
KIAA1147 KIAA1147 −1.8
KIAA1211 KIAA1211 −2.6
Kinesin family member 13B KIF13B −2.0 (1)
Kinesin family member 26B KIF26B −2.5
Kinesin family member 5C KIF5C −5.0
Kelch domain containing 9 KLHDC9 −2.6
Kelch-like 29 (Drosophila) KLHL29 −2.5
Kynureninase (L-kynurenine hydrolase) KYNU −2.6 (1) MES
Laminin, α 1 LAMA1 −3.1
Lymphoid enhancer-binding factor 1 LEF1 −3.2
LEM domain containing 1 LEMD1 −5.2
Lectin, galactoside-binding, soluble, 9B LGALS9B −1.9
Leucine-rich repeat LGI family, member 2 LGI2 −3.9
Leukemia inhibitory factor receptor α LIFR −2.3
LIM domain kinase 1 LIMK1 −2.9
Long intergenic nonprotein coding RNA 341 LINC00341 −2.1
Long intergenic nonprotein coding RNA 623 LINC00623 −3.2
Lipase, endothelial LIPG −3.1
LOC100128288 −1.8
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LON peptidase N-terminal domain and ring finger 1 LONRF1 −2.7
LON peptidase N-terminal domain and ring finger 2 LONRF2 −2.9 (1)
Lysophosphatidic acid receptor 1 LPAR1 −1.9
Latrophilin 3 LPHN3 −2.0 (1) PN
Lipoprotein lipase LPL −4.2
Lipid phosphate phosphatase-related protein type 5 LPPR5 −4.4
Low-density lipoprotein–related protein 1 (α-2-macroglobulin receptor) LRP1 −1.9
Low-density lipoprotein–related protein 1B (deleted in tumors) LRP1B −2.5 (1)
Low-density lipoprotein receptor–related protein 4 LRP4 −3.0
Leucine rich repeat containing 4C LRRC4C −3.4 (1)
Leucine rich repeat neuronal 2 LRRN2 −4.5
Leucine rich repeat neuronal 3 LRRN3 −2.5
LY6/PLAUR domain containing 1 LYPD1 −2.7
Leucine zipper, putative tumor suppressor 1 LZTS1 −4.8
Mal, T cell differentiation protein MAL −4.8
MAM domain containing 2 MAMDC2 −3.2 (1)
Mannosidase, α, class 1C, member 1 MAN1C1 −3.9
Mitogen-activated protein kinase kinase 5 MAP2K5 −3.1
Mitogen-activated protein kinase 10 MAPK10 −1.8 (1)
Mitogen-activated protein kinase 4 MAPK4 −2.1
Mitogen-activated protein kinase 8 interacting protein 1 MAPK8IP1 −2.8
MARCKS-like 1 MARCKSL1 −2.1 PN
Midkine (neurite growth-promoting factor 2) MDK −2.4
Mesenchyme homeobox 2 MEOX2 −2.0 (1) CL
Meteorin, glial cell differentiation regulator METRN −3.1
Major facilitator superfamily domain containing 6 MFSD6 −1.9
Matrix Gla protein MGP −1.9
MKL/myocardin-like 2 MKL2 −2.9
Megalencephalic leukoencephalopathy with subcortical cysts 1 MLC1 −2.4
Musashi homolog 1 (Drosophila) MSI1 −2.1
Microseminoprotein, prostate associated MSMP −4.6
Metallothionein 1X MT1X −2.2
Myosin binding protein C, slow type MYBPC1 −5.0 NL
Myosin VB MYO5B −1.9
Neurocan NCAN −2.9
Noncompact myelin associated protein NCMAP −2.5
NDRG family member 4 NDRG4 −3.2
NEL-like 2 (chicken) NELL2 −2.5
Nestin NES −4.5 (5) CL
Nuclear factor I/B NFIB −3.0 (1)
Nuclear factor of κ light polypeptide gene enhancer in B cells inhibitor, β NFKBIB −2.7
Neuroligin 4, X-linked NLGN4X −1.8 (1)
Neuroligin 4, Y-linked NLGN4Y −7.3
Nicotinamide nucleotide adenylyltransferase 2 NMNAT2 −3.6
Nicotinamide nucleotide adenylyltransferase 3 NMNAT3 −2.1 (1)
Neuro-oncological ventral antigen 1 NOVA1 −2.7 (1)
Neuronal PAS domain protein 2 NPAS2 −3.9
Neuronal PAS domain protein 3 NPAS3 −3.3 (1) CL
Neuropeptide B NPB −2.6
Neuropeptide Y receptor Y5 NPY5R −6.6
Notch-regulated ankyrin repeat protein NRARP −3.2
Neuronal cell adhesion molecule NRCAM −4.3
Neurogranin (protein kinase C substrate, RC3) NRGN −2.8 (1)
Neuropilin 2 NRP2 −1.8 (1)
Netrin 1 NTN1 −2.2 (1)
OAF homolog (Drosophila) OAF −2.4
Olfactomedin-like 3 OLFML3 −2.6
Oxysterol binding protein-like 6 OSBPL6 −2.4 (1)
Orthopedia homeobox OTP −2.2
Prostate androgen-regulated mucin-like protein 1 PARM1 −4.2
Protocadherin 20 PCDH20 −3.4
Protocadherin 9 PCDH9 −6.4 (1)
Protocadherin γ subfamily A, 5 PCDHGA5 −2.5
Protocadherin γ subfamily C, 3 PCDHGC3 −2.0
Phosphodiesterase 1B, calmodulin-dependent PDE1B −5.2
Phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 dunce homolog, Drosophila) PDE4B −2.1 (1)
Phosphodiesterase 8B PDE8B −3.3 (1)
Platelet-derived growth factor receptor, α polypeptide PDGFRA −4.2 (2)
PDZ and LIM domain 4 PDLIM4 −2.4
Podoplanin PDPN −6.8 MES
Paternally expressed 10 PEG10 −2.6
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Pellino homolog 1 (Drosophila) PELI1 −2.9 PN
GPI deacylase PGAP1 −2.8 (1)
PiggyBac transposable element derived 5 PGBD5 −2.9 NL
Pleckstrin homology-like domain, family A, member 1 PHLDA1 −2.0
Phosphatidylinositol glycan anchor biosynthesis, class F PIGF −3.8
Protein (peptidylprolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin) PIN4 −2.1
Pigeon homolog (Drosophila) PION −2.2
Phosphatidylinositol transfer protein, cytoplasmic 1 PITPNC1 −3.2
Protein kinase (cAMP-dependent, catalytic) inhibitor α PKIA −2.6 (1)
Protein kinase (cAMP-dependent, catalytic) inhibitor β PKIB −3.3
Phospholipase C, γ 1 PLCG1 −3.1
Phospholipase D family, member 3 PLD3 −3.0
Pleckstrin homology domain containing, family B (evectins) member 1 PLEKHB1 −3.1 (1)
Pleckstrin homology domain containing, family G (with ρGef domain) member 1 PLEKHG1 −2.4
Prostate transmembrane protein, androgen induced 1 PMEPA1 −4.5
Paraneoplastic antigen MA2 PNMA2 −3.4 (1)
Podocalyxin-like 2 PODXL2 −1.9 PN
POM (POM121 homolog, rat) and ZP3 fusion POMZP3 −4.4
Periostin, osteoblast specific factor POSTN −5.7 (1)
Phosphatidic acid phosphatase type 2C PPAP2C −2.5
Protein phosphatase 1, catalytic subunit, β isoform PPP1CB −1.8
Protein kinase, cAMP-dependent, catalytic, β PRKACB −1.8
Protein kinase C, θ PRKCQ −2.2
Proline rich 7 (synaptic) PRR7 −2.2
Prostaglandin F2 receptor negative regulator PTGFRN −2.3 (1)
Prothymosin, α (gene sequence 28) PTMA −1.9
Pleiotrophin (heparin binding growth factor 8, neurite growth-promoting factor 1) PTN −2.4
Protein tyrosine phosphatase, nonreceptor type 12 PTPN12 −1.9
Protein tyrosine phosphatase, nonreceptor type 13 (APO-1/CD95 (Fas)-associated phosphatase) PTPN13 −2.4 (1)
Protein tyrosine phosphatase, receptor type, D PTPRD −6.4 (1)
RAB36, member RAS oncogene family RAB36 −3.5
RAN binding protein 2 RANBP2 −2.3
Rap guanine nucleotide exchange factor (GEF) 5 RAPGEF5 −5.4
RAS, dexamethasone-induced 1 RASD1 −1.9
Ras interacting protein 1 RASIP1 −4.1
Ras association (RalGDS/AF-6) domain family 2 RASSF2 −3.0
Retinol binding protein 7, cellular RBP7 −2.5
Regulator of calcineurin 2 RCAN2 −2.2
Receptor accessory protein 1 REEP1 −2.1 (1) PN
Replication factor C (activator 1) 2, 40kDa RFC2 −1.9
Raftlin family member 2 RFTN2 −4.9
Regulator of G-protein signaling 2, 24kDa RGS2 −3.2 (1)
Rhomboid domain containing 3 RHBDD3 −2.2
Ras homolog gene family, member U RHOU −3.0 (1)
Regulating synaptic membrane exocytosis 4 RIMS4 −2.6
Ρ family GTPase 2 RND2 −1.9
Ring finger protein 112 RNF112 −2.0
Reticulon 1 RTN1 −4.2
Sal-like 1 (Drosophila) SALL1 −7.3 (1)
Sterile α motif domain containing 13 SAMD13 −2.7
Sterile α motif domain containing 5 SAMD5 −3.4
Secretogranin II (chromogranin C) SCG2 −3.0
Sodium channel, voltage-gated, type IV, β SCN4B −2.4
Sodium channel, voltage-gated, type IX, α subunit SCN9A −1.9 (1)
Scrapie responsive protein 1 SCRG1 −5.0 (1)
Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A SEMA3A −2.5 (1)
Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E SEMA3E −5.1
Sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A SEMA6A −2.5 (1) CL
Selenoprotein N, 1 SEPN1 −2.2
Septin 3 SEPT3 −2.2
Septin 5 SEPT5 −2.0
SET binding protein 1 SETBP1 −2.0 (1)
Sideroflexin 5 SFXN5 −3.7 (1)
Sarcoglycan, ε SGCE −6.4
Homolog of rat pragma of Rnd2 SGK223 −2.4
SH3 and PX domains 2A SH3PXD2A −2.1 (1)
SHC (Src homology 2 domain containing) family, member 4 SHC4 −6.8 (1)
SLAIN motif family, member 1 SLAIN1 −3.9
Solute carrier family 10 (sodium/bile acid cotransporter family), member 4 SLC10A4 −3.3
Solute carrier family 1 (glial high affinity glutamate transporter), member 3 SLC1A3 −1.9 (1)
Solute carrier family 25, member 13 (citrin) SLC25A13 −2.0 (1)
Solute carrier family 25 (mitochondrial carrier), member 18 SLC25A18 −3.6
206.e6 Sox2 Has Multiple Functions in Glioblastoma Berezovsky et al. Neoplasia Vol. 16, No. 3, 2014
TABLE W1. (continued)
SDC
Description Symbol Fold Change
(Log2)
Sox2 Target
(Ref)
Subclass
Signature
Solute carrier family 26, member 7 SLC26A7 −2.4
Solute carrier family 27 (fatty acid transporter), member 1 SLC27A1 −2.0
Solute carrier family 35, member B4 SLC35B4 −2.1
Solute carrier family 35, member F1 SLC35F1 −3.1
Solute carrier family 39 (zinc transporter), member 12 SLC39A12 −3.0
Solute carrier family 45, member 3 SLC45A3 −5.6
Solute carrier family 4, anion exchanger, member 3 SLC4A3 −3.8 (1)
Solute carrier organic anion transporter family, member 2A1 SLCO2A1 −3.7
Solute carrier organic anion transporter family, member 5A1 SLCO5A1 −2.5 PN
SLIT and NTRK-like family, member 3 SLITRK3 −4.1
Sarcolipin SLN −6.4
SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily d, member 3 SMARCD3 −1.9 (1)
Structural maintenance of chromosomes 6 SMC6 −2.6
Smoothened homolog (Drosophila) SMO −2.3 (1) CL
Sine oculis binding protein homolog (Drosophila) SOBP −1.9
Suppressor of cytokine signaling 2 SOCS2 −2.5 (1) CL
Sortilin-related receptor, L(DLR class) A repeats-containing SORL1 −3.1
SRY (sex-determining region Y)-box 15 SOX15 −3.5
SRY (sex-determining region Y)-box 2 SOX2 −4.0 PN
SRY (sex-determining region Y)-box 21 SOX21 −3.1 (1) (2)
SRY (sex-determining region Y)-box 3 SOX3 −4.4
SRY (sex-determining region Y)-box 8 SOX8 −3.1
SPARC-like 1 (mast9, hevin) SPARCL1 −2.4
Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 SPOCK2 −4.0
Spondin 1, extracellular matrix protein SPON1 −4.9
Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1) SPP1 −5.2
Sprouty homolog 1, antagonist of FGF signaling (Drosophila) SPRY1 −3.1 (1)
Sprouty homolog 2 (Drosophila) SPRY2 −2.2 (1) CL
Sprouty homolog 4 (Drosophila) SPRY4 −1.9 (1)
SLIT-ROBO Ρ GTPase activating protein 3 SRGAP3 −2.0 (1) PN
Sorcin SRI −2.8 (1)
SFRS protein kinase 2 SRPK2 −4.0 (1)
Sushi-repeat-containing protein, X-linked SRPX −2.6
Single stranded DNA binding protein 4 SSBP4 −2.5 (1)
ST6 β-galactosamide α-2,6-sialyltranferase 1 ST6GAL1 −3.9
Stanniocalcin 1 STC1 −2.3
Serine/threonine kinase 32A STK32A −2.2
Storkhead box 2 STOX2 −3.2
Syntaxin 1A (brain) STX1A −2.1
Syntabulin (syntaxin-interacting) SYBU −2.1
Synemin, intermediate filament protein SYNM −2.2
TAF6 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 80kDa TAF6 −3.4
Transgelin 3 TAGLN3 −3.4
Transcobalamin II; macrocytic anemia TCN2 −2.8
Tyrosyl-DNA phosphodiesterase 1 TDP1 −2.4
Transforming growth factor, α TGFA −2.5 (1)
Thrombospondin 2 THBS2 −2.6
TIMP metallopeptidase inhibitor 4 TIMP4 −4.5
Tousled-like kinase 1 TLK1 −2.0 (1)
Transmembrane 7 superfamily member 2 TM7SF2 −2.1
Transmembrane protein 108 TMEM108 −2.3 (1)
Transmembrane protein 132A TMEM132A −2.2
Transmembrane protein 163 TMEM163 −3.2 (1)
Transmembrane protein 255A TMEM255A −2.6
Transmembrane protein 26 TMEM26 −2.3
Transmembrane protein 55A TMEM55A −1.9
Transmembrane protein 86A TMEM86A −4.0
Transmembrane and tetratricopeptide repeat containing 2 TMTC2 −5.2 (1)
Tumor necrosis factor, α-induced protein 6 TNFAIP6 −4.6
Tumor necrosis factor (ligand) superfamily, member 15 TNFSF15 −2.6
Tumor necrosis factor (ligand) superfamily, member 4 (tax-transcriptionally activated glycoprotein 1, 34kDa) TNFSF4 −6.9
TP53 target 1 (nonprotein coding) TP53TG1 −1.8
Tumor protein D52 TPD52 −1.8 (1)
Tubulin polyglutamylase complex subunit 2 TPGS2 −2.7
Thiamin pyrophosphokinase 1 TPK1 −6.3 (1)
Tribbles homolog 2 (Drosophila) TRIB2 −2.0 (1) CL
TLR4 interactor with leucine-rich repeats TRIL −2.9
Tripartite motif-containing 36 TRIM36 −1.9 (1)
Tripartite motif-containing 47 TRIM47 −3.1
Tripartite motif-containing 9 TRIM9 −3.3
Trichorhinophalangeal syndrome I TRPS1 −2.2 (1)
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Thiosulfate sulfurtransferase (rhodanese)-like domain containing 1 TSTD1 −4.6
Tubulin tyrosine ligase-like family, member 4 TTLL4 −2.8
Tweety homolog 1 (Drosophila) TTYH1 −4.2
Tweety homolog 3 (Drosophila) TTYH3 −2.4 (1)
Tubulin, β 2B TUBB2B −4.5
Ubiquitin specific peptidase 14 (tRNA-guanine transglycosylase) USP14 −2.1
Vang-like 2 (van gogh, Drosophila) VANGL2 −1.9
VGF nerve growth factor inducible VGF −2.0
Visinin-like 1 VSNL1 −1.9 (1)
V-set and transmembrane domain containing 2 like VSTM2L −1.9
Von Willebrand factor A domain containing 1 VWA1 −3.0
Wiskott-Aldrich syndrome (eczema-thrombocytopenia) WAS −2.5
WAS/WASL interacting protein family, member 1 WIPF1 −4.0 MES
Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, γ polypeptide YWHAG −1.9
Zinc finger and BTB domain containing 7C ZBTB7C −6.5 (1)
Zic family member 2 (odd-paired homolog, Drosophila) ZIC2 −3.3
Zinc finger, matrin type 4 ZMAT4 −4.2 (1)
Zinc finger protein 226 ZNF226 −1.9
Zinc finger protein 3 ZNF3 −2.1
Zinc finger protein 331 ZNF331 −2.0
Zinc finger protein 573 ZNF573 −1.8
Zinc finger protein 615 ZNF615 −2.0
Zinc finger protein 679 ZNF679 −4.4
Zinc finger protein 680 ZNF680 −2.4 (1)
Zinc finger protein 681 ZNF681 −2.0
ABI gene family, member 3 (NESH) binding protein ABI3BP 2.1 (1)
Ankyrin repeat and BTB (POZ) domain containing 1 ABTB1 2.5
Adenosine A2b receptor ADORA2B 2.0
Adrenergic, α-1B-, receptor ADRA1B 2.0 (1)
Adrenergic, β-2-, receptor, surface ADRB2 4.0 (1)
AGSK1 1.8
Ajuba LIM protein AJUBA 2.4
Adenylate kinase 4 AK4 1.9
Aldo-keto reductase family 1, member C1 AKR1C1 6.3
Aldo-keto reductase family 1, member C3 (3-α hydroxysteroid dehydrogenase, type II) AKR1C3 2.2
Aldo-keto reductase family 1, member C4 (chlordecone reductase; 3-α hydroxysteroid dehydrogenase, type I;
dihydrodiol dehydrogenase 4)
AKR1C4 3.7
Activated leukocyte cell adhesion molecule ALCAM 2.2 (1)
Angiopoietin-like 2 ANGPTL2 2.0
Ankyrin repeat domain 1 (cardiac muscle) ANKRD1 4.0
Alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150) ANPEP 2.3
Annexin A11 ANXA11 2.7
Annexin A3 ANXA3 4.9 NL
Annexin A6 ANXA6 2.0
Adenomatosis polyposis coli down-regulated 1-like APCDD1L 2.3 (1)
Ρ GTPase activating protein 30 ARHGAP30 1.8
Ρ GDP dissociation inhibitor (GDI) β ARHGDIB 2.8
Ρ guanine nucleotide exchange factor (GEF) 10 ARHGEF10 2.5
Aspartate β-hydroxylase ASPH 2.2 (1)
Argininosuccinate synthetase 1 ASS1 2.1
Arginine vasopressin-induced 1 AVPI1 2.1
AXL receptor tyrosine kinase AXL 2.3 (1)
Brain abundant, membrane attached signal protein 1 BASP1 2.6 (1) NL
Breast cancer anti-estrogen resistance 3 BCAR3 2.9
Brain-derived neurotrophic factor BDNF 2.0
BEN domain containing 7 BEND7 2.1
Chromosome 11 open reading frame 75 C11orf75 3.2
Chromosome 11 open reading frame 87 C11orf87 1.9
Calmodulin-like 4 CALML4 3.0
Caspase 4, apoptosis-related cysteine peptidase CASP4 2.3 MES
Castor zinc finger 1 CASZ1 2.9
Caveolin 1, caveolae protein, 22kDa CAV1 1.9
Coiled-coil domain containing 147 CCDC147 2.3
Coiled-coil domain containing 80 CCDC80 2.8
Cyclin D1 CCND1 5.7 (1)
CD163 molecule-like 1 CD163L1 3.0
CD24 molecule CD24 4.9
CDC14 cell division cycle 14 homolog B (Saccharomyces cerevisiae) CDC14B 2.3
Cadherin 11, type 2, OB-cadherin (osteoblast) CDH11 2.0 (1)
Cadherin 13, H-cadherin (heart) CDH13 4.4 (1)
Complement factor B CFB 2.9
Chorionic gonadotropin, β polypeptide CGB 2.2
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Chorionic gonadotropin, β polypeptide 1 CGB1 4.3
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 CITED2 2.1 (1)
Cytidine monophospho-N-acetylneuraminic acid hydroxylase, pseudogene CMAHP 2.2
CKLF-like MARVEL transmembrane domain containing 7 CMTM7 2.5
Calponin 1, basic, smooth muscle CNN1 3.8
Calponin 2 CNN2 2.0 MES
Collagen, type XI, α 1 COL11A1 1.8 (1)
Collagen, type XII, α 1 COL12A1 2.9 (1)
Collagen, type V, α 1 COL5A1 2.9 (1) MES
Collagen, type VI, α 2 COL6A2 1.8
Collagen, type VIII, α 1 COL8A1 1.9
Coronin, actin binding protein, 2A CORO2A 2.0
Carboxypeptidase A4 CPA4 3.9 (1)
Cadherin-like and PC-esterase domain containing 1 CPED1 2.2
Colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog CSF1R 2.9
Chondroitin sulfate proteoglycan 4 CSPG4 3.7
C-terminal binding protein 2 CTBP2 2.6 (1)
Connective tissue growth factor CTGF 1.9
Cathepsin H CTSH 2.2
Chemokine (C-X-C motif) receptor 7 CXCR7 2.8 (1)
Cytochrome P450, family 26, subfamily B, polypeptide 1 CYP26B1 2.4 (1)
Cysteine-rich, angiogenic inducer, 61 CYR61 2.7
Cytohesin 3 CYTH3 1.8
Disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) DAB2 3.4 MES
DEP domain containing 7 DEPDC7 2.7
Deiodinase, iodothyronine, type II DIO2 2.0
DIX domain containing 1 DIXDC1 1.9
Dickkopf homolog 1 (Xenopus laevis) DKK1 3.2 (4)
DnaJ (Hsp40) homolog, subfamily B, member 12 DNAJB12 2.1
Dedicator of cytokinesis 2 DOCK2 1.9 (1)
Dermatan sulfate epimerase DSE 2.2 MES
Deltex 3-like (Drosophila) DTX3L 1.9
Dual specificity phosphatase 1 DUSP1 2.0 (1)
Endothelin converting enzyme 2 ECE2 3.7 (1)
EH-domain containing 4 EHD4 2.2 (1)
Elongation factor, RNA polymerase II, 2 ELL2 1.8 (1)
ELM2 and Myb/SANT-like domain containing 1 ELMSAN1 1.9
Ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin) ENPP2 2.8 NL
V-ets erythroblastosis virus E26 oncogene homolog 2 (avian) ETS2 4.2 (1)
Eyes absent homolog 1 (Drosophila) EYA1 4.0
Coagulation factor III (thromboplastin, tissue factor) F3 2.6
Family with sequence similarity 133, member A FAM133A 2.3
Family with sequence similarity 24, member B FAM24B 3.3
Fibrillin 1 FBN1 1.9
Fibroblast growth factor 13 FGF13 2.4 (1)
Filamin A interacting protein 1-like FILIP1L 1.9
Hypothetical LOC642477 FLJ39632 3.4
Fibronectin leucine rich transmembrane protein 2 FLRT2 3.0 (1)
Folate receptor 1 (adult) FOLR1 3.5
Forkhead box C1 FOXC1 2.9
Fraser syndrome 1 FRAS1 3.4
Follistatin FST 3.5
FXYD domain containing ion transport regulator 5 FXYD5 3.3 MES
Frizzled homolog 2 (Drosophila) FZD2 2.4 (1)
Growth arrest-specific 6 GAS6 4.1
Guanylate binding protein 2, interferon-inducible GBP2 2.7
Growth differentiation factor 15 GDF15 1.8
Glucose-fructose oxidoreductase domain containing 1 GFOD1 2.8
GDNF family receptor α 1 GFRA1 2.6
Gap junction protein, γ 12, 47kDa GJC2 2.3
G protein-coupled receptor 1 GPR1 2.4 (1)
G protein-coupled receptor, family C, group 5, member C GPRC5C 2.3 (1)
Glutathione peroxidase 3 (plasma) GPX3 2.3
GRAM domain containing 3 GRAMD3 2.7
Gasdermin A GSDMA 2.1
H2A histone family, member Y2 H2AFY2 2.2
HLA complex P5 HCP5 2.3
Hairy and enhancer of split 6 (Drosophila) HES6 2.9
Homeobox C13 HOXC13 2.3
Homeobox C6 HOXC6 2.1
Heat shock 27kDa protein 3 HSPB3 2.1
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Heat shock 27kDa protein family, member 7 (cardiovascular) HSPB7 6.0
Immediate early response 3 IER3 2.2
Interferon induced transmembrane protein 1 IFITM1 2.5
Insulin-like growth factor binding protein 4 IGFBP4 3.5
Interleukin 13 receptor, α 2 IL13RA2 3.4
Interleukin 15 IL15 2.1 (1)
Interleukin 7 receptor IL7R 2.4
Integrin, α 11 ITGA11 2.2
Integrin, β 2 (complement component 3 receptor 3 and 4 subunit) ITGB2 3.6 MES
Jagged 2 JAG2 2.1
Junctophilin 2 JPH2 2.0
Kazrin, periplakin interacting protein KAZN 3.0
Potassium voltage-gated channel, Shab-related subfamily, member 1 KCNB1 3.4
Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 1 KCNS1 1.8
KIAA1522 KIAA1522 2.0 (1)
Kruppel-like factor 11 KLF11 1.9
Killin, p53-regulated DNA replication inhibitor KLLN 1.9
Keratin 18 pseudogene 55 KRT18P55 3.0
Keratin 80 KRT80 3.8
Keratin 81 KRT81 6.8
Lactamase, β LACTB 2.0
Layilin LAYN 1.9
Leprecan-like 1 LEPREL1 3.2
LIM and senescent cell antigen-like domains 2 LIMS2 4.6
Long intergenic nonprotein coding RNA 263 LINC00263 2.8
LOC400464 2.0
LOC400879 2.0
LOC645638 3.6
Lysyl oxidase LOX 3.0 MES
Leucine rich repeat neuronal 1 LRRN1 1.9 (1)
Melanoma antigen family C, 2 MAGEC2 2.4 (1)
Mitogen-activated protein kinase 13 MAPK13 3.2 MES
Membrane-associated ring finger (C3HC4) 3 MARCH3 1.9
Mab-21 domain containing 2 MB21D2 3.4
Meis homeobox 3 pseudogene 1 MEIS3P1 1.8
Microfibrillar-associated protein 4 MFAP4 1.8
Microtubule associated monoxygenase, calponin and LIM domain containing 2 MICAL2 3.0 (1)
MHC class I polypeptide-related sequence B MICB 2.1
Mohawk homeobox MKX 3.3
Melanophilin MLPH 2.9
Matrix metallopeptidase 3 (stromelysin 1, progelatinase) MMP3 3.2
Mesothelin MSLN 3.8
Methionine sulfoxide reductase B3 MSRB3 3.7
Mucin 1, cell surface associated MUC1 1.9
Matrix-remodelling associated 8 MXRA8 2.2
Myosin, light chain 1, alkali; skeletal, fast MYL1 3.7 (1)
Myosin, light chain 9, regulatory MYL9 3.4
Myosin IC MYO1C 2.9
Nucleosome assembly protein 1-like 3 NAP1L3 1.8
Neuroblastoma, suppression of tumorigenicity 1 NBL1 3.4
Neutral cholesterol ester hydrolase 1 NCEH1 2.0
Neutrophil cytosolic factor 2 (65kDa, chronic granulomatous disease, autosomal 2) NCF2 3.6 MES
NIMA (never in mitosis gene a)-related kinase 7 NEK7 2.8
Nexilin (F actin binding protein) NEXN 2.5 (1)
NK2 homeobox 2 NKX2-2 1.9 PN
Neuromedin U NMU 2.1
N-terminal Xaa-Pro-Lys N-methyltransferase 1 NTMT1 1.9
Netrin G1 NTNG1 3.8 (1)
Nuclear casein kinase and cyclin-dependent kinase substrate 1 NUCKS1 4.7
Opioid growth factor receptor-like 1 OGFRL1 2.4
Oxytocin receptor OXTR 1.9
Procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), α polypeptide II P4HA2 2.0 MES
P antigen family, member 5 (prostate associated) PAGE5 4.2
Palmdelphin PALMD 3.1
3′-phosphoadenosine 5′-phosphosulfate synthase 2 PAPSS2 3.5
Paired box 6 PAX6 2.0
Platelet-derived growth factor receptor-like PDGFRL 2.3
PDZ and LIM domain 1 (elfin) PDLIM1 2.9
Phosphoglucomutase 3 PGM3 1.8
Pleckstrin homology-like domain, family B, member 2 PHLDB2 2.3
Paired-like homeodomain 2 PITX2 4.7 (1)
Placenta-specific 8 PLAC8 2.9
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Pleiomorphic adenoma gene-like 1 PLAGL1 2.0
Pleckstrin homology domain containing, family F (with FYVE domain) member 1 PLEKHF1 2.7
Phospholipid scramblase 4 PLSCR4 2.6
Plexin A2 PLXNA2 1.9 (1)
Phosphatidic acid phosphatase type 2 domain containing 1A PPAPDC1A 2.4
Prickle homolog 1 (Drosophila) PRICKLE1 2.9
Proline rich 16 PRR16 2.6 (1)
Protease, serine, 23 PRSS23 2.6
Pregnancy specific β-1-glycoprotein 4 PSG4 5.0
Protein tyrosine phosphatase, receptor type, F PTPRF 2.4
Protein tyrosine phosphatase, receptor type, M PTPRM 1.9 (1)
RAB32, member RAS oncogene family RAB32 2.1 MES
RAB3B, member RAS oncogene family RAB3B 5.1
Retinoic acid early transcript 1G RAET1G 2.2
Retinoic acid receptor, β RARB 3.9
Retinoic acid receptor responder (tazarotene induced) 2 RARRES2 2.6
Ras association (RalGDS/AF-6) domain family 7 RASSF7 1.8
RNA binding motif, single stranded interacting protein RBMS3 1.9 (1)
RNA binding protein with multiple splicing RBPMS 2.5 (1)
Reticulocalbin 3, EF-hand calcium binding domain RCN3 1.9
Reversion-inducing-cysteine-rich protein with kazal motifs RECK 1.9
RAS-like, estrogen-regulated, growth inhibitor RERG 4.1
Raftlin, lipid raft linker 1 RFTN1 3.7
RGM domain family, member B RGMB 1.9
Regulator of G-protein signaling 10 RGS10 1.8
Rhomboid 5 homolog 2 (Drosophila) RHBDF2 2.4
Ribonuclease, RNase A family, 4 RNASE4 2.4
Ring finger protein 150 RNF150 2.7
Arginyl aminopeptidase (aminopeptidase B) RNPEP 1.8
Ribosomal protein S6 kinase, 90kDa, polypeptide 2 RPS6KA2 2.2
Related RAS viral (r-ras) oncogene homolog 2 RRAS2 2.1 (1)
Sodium channel, nonvoltage-gated 1 α SCNN1A 3.5
Serologically defined colon cancer antigen 3 SDCCAG3 2.3
Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B SEMA3B 3.1
Serpin peptidase inhibitor, clade B (ovalbumin), member 7 SERPINB7 3.1 (1)
SERTA domain containing 4 SERTAD4 3.2
SERTAD4 antisense RNA 1 SERTAD4-AS1 3.3
Surfactant associated 1, pseudogene SFTA1P 2.3
SH2 domain containing 4A SH2D4A 2.4
SH3-domain GRB2-like 3 SH3GL3 7.2 (1) NL
SH3 domain containing ring finger 2 SH3RF2 2.8
Solute carrier family 1 (neutral amino acid transporter), member 5 SLC1A5 2.0
Solute carrier family 22 (organic cation transporter), member 4 SLC22A4 1.8
Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 24 SLC25A24 1.9
Solute carrier family 25, member 43 SLC25A43 2.0
Solute carrier family 38, member 1 SLC38A1 3.2 (1)
Solute carrier family 6 (neurotransmitter transporter, glycine), member 9 SLC6A9 2.0 CL
Solute carrier family 9 (sodium/hydrogen exchanger), member 7 SLC9A7 2.3
SMAD family member 6 SMAD6 3.1 (1)
Smg-6 homolog, nonsense mediated mRNA decay factor (C. elegans) SMG6 2.1
Sosondowah ankyrin repeat domain family member A SOWAHA 2.5
SPANX family, member C SPANXC 2.9 (1)
SPANX family, member E SPANXE 4.9
SPATA31 subfamily C, member 2 SPATA31C2 2.2
Sphingosine kinase 1 SPHK1 2.0
Serine palmitoyltransferase, long chain base subunit 3 SPTLC3 3.0
Serglycin SRGN 3.1
Slingshot homolog 3 (Drosophila) SSH3 2.0 CL
Sjogren syndrome/scleroderma autoantigen 1 SSSCA1 2.2 (1)
ST6 (α-N-acetyl-neuraminyl-2,3-β-galactosyl-1,3)-N-acetylgalactosaminide α-2,6-sialyltransferase 3 ST6GALNAC3 2.0 (1)
StAR-related lipid transfer (START) domain containing 5 STARD5 1.9 (1)
StAR-related lipid transfer (START) domain containing 8 STARD8 2.2 (1)
Stanniocalcin 2 STC2 3.5
Syntaxin binding protein 5 (tomosyn) STXBP5 2.7 (1)
Syncoilin, intermediate filament protein SYNC 2.3
Transgelin TAGLN 3.3
TEA domain family member 4 TEAD4 3.1
Teneurin transmembrane protein 4 TENM4 2.2
Transforming growth factor, β 2 TGFB2 6.5
Transforming growth factor, β receptor III TGFBR3 2.6
Thrombospondin 1 THBS1 2.7 (1) MES
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TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy, pseudoinflammatory) TIMP3 4.6
Transmembrane protein 255B TMEM255B 2.0
Transmembrane protein 44 TMEM44 1.9
Transmembrane protein 45A TMEM45A 2.3 (1)
Tumor protein p53 inducible protein 11 TP53I11 2.8 (1)
Two pore segment channel 2 TPCN2 2.0
Tropomyosin 1 (α) TPM1 2.0
Tropomyosin 2 (β) TPM2 1.8
Tetraspanin 10 TSPAN10 2.9
Tetraspanin 4 TSPAN4 2.1
Tuftelin 1 TUFT1 2.5
Thioredoxin interacting protein TXNIP 1.8
Urothelial cancer associated 1 UCA1 2.4
Vascular endothelial growth factor C VEGFC 1.8
WAS protein family, member 3 WASF3 1.9
Wingless-type MMTV integration site family member 2 WNT2 3.3
Wingless-type MMTV integration site family, member 3 WNT3 3.1
Wingless-type MMTV integration site family, member 5B WNT5B 3.6
WW and C2 domain containing 1 WWC1 2.1
Yip1 interacting factor homolog A (Saccharomyces cerevisiae) YIF1A 1.9
Zinc finger, CCHC domain containing 5 ZCCHC5 3.1 (1)
Zinc finger protein 618 ZNF618 2.2
Zinc finger protein 730 ZNF730 1.8
CSC
Description Symbol Fold Change
(Log2)
Sox2 Target
(Ref)
Subclass
Signature
AP2 associated kinase 1 AAK1 −2.5 (1)
ATP-binding cassette, subfamily A (ABC1), member 2 ABCA2 −2.5
Acetylcholinesterase (Yt blood group) ACHE −2.2
Acid phosphatase 6, lysophosphatidic ACP6 −2.7
Acyl-CoA synthetase short-chain family member 1 ACSS1 −2.0
Activin A receptor, type IIA ACVR2A −3.5 (1)
Adenosine deaminase ADA −2.1
ADAM metallopeptidase domain 15 ADAM15 −2.1
ADAM metallopeptidase with thrombospondin type 1 motif, 6 ADAMTS6 −2.2 (1)
ADAM metallopeptidase with thrombospondin type 1 motif, 8 ADAMTS8 −3.9 (1)
Angiotensinogen (serpin peptidase inhibitor, clade A, member 8) AGT −2.1
Allograft inflammatory factor 1-like AIF1L −2.3
Adenylate kinase 4 AK4 −2.5
A kinase (PRKA) anchor protein 10 AKAP10 −1.8
V-akt murine thymoma viral oncogene homolog 2 AKT2 −1.8 CL
Aldehyde dehydrogenase 4 family, member A1 ALDH4A1 −2.1
Aldehyde dehydrogenase 6 family, member A1 ALDH6A1 −2.7
Antagonist of mitotic exit network 1 homolog (Saccharomyces cerevisiae) AMN1 −2.1
Angiopoietin 2 ANGPT2 −4.3
Ρ guanine nucleotide exchange factor (GEF) 39 ARHGEF39 −1.8
ADP-ribosylation factor-like 4A ARL4A −2.9 (1)
Arylsulfatase G ARSG −1.8
Ankyrin repeat and SOCS box-containing 9 ASB9 −3.6 (1)
Asparaginase like 1 ASRGL1 −2.1
Astrotactin 1 ASTN1 −2.0
Autophagy related 13 ATG13 −3.6
ATPase type 13A4 ATP13A4 −3.6
ATPase, Na+/K+ transporting, β 2 polypeptide ATP1B2 −2.3
ATPase, class II, type 9B ATP9B −2.1 (1)
ATP binding domain 4 ATPBD4 −1.9
UDP-GlcNAc:βGal β-1,3-N-acetylglucosaminyltransferase 2 B3GNT2 −2.0 (1)
Bardet-Biedl syndrome 9 BBS9 −3.1
B cell receptor-associated protein 29 BCAP29 −6.0
B-box and SPRY domain containing BSPRY −2.1
Βcellulin BTC −2.2 (1)
Chromosome 10 open reading frame 12 C10orf12 −2.4
Chromosome 11 open reading frame 63 C11orf63 −2.4
Chromosome 19 open reading frame 6 C19orf6 −1.8
Chromosome 2 open reading frame 80 C2orf80 −5.8
Chromosome 6 open reading frame 15 C6orf15 −2.0
Chromosome 6 open reading frame 170 C6orf170 −1.9
Carbonic anhydrase II CA2 −4.3
Carbonic anhydrase IV CA4 −2.4 (1) NL
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Calcium channel, voltage-dependent, P/Q type, α 1A subunit CACNA1A −2.8 (1)
Calcium channel, voltage-dependent, β 1 subunit CACNB1 −2.6
Cell adhesion molecule 1 CADM1 −4.5
Ca2+−dependent activator protein for secretion 2 CADPS2 −2.0 (1)
Calpain 9 CAPN9 −2.8 (1)
Calcyphosine CAPS −2.3
Coiled-coil domain containing 103 CCDC103 −4.3
Coiled-coil domain containing 94 CCDC94 −2.2
CD14 molecule CD14 −2.2 MES
CD276 molecule CD276 −2.4
CD79b molecule, immunoglobulin-associated β CD79B −2.1
Cadherin 6, type 2, K-cadherin (fetal kidney) CDH6 −3.1 (1) CL
Carcinoembryonic antigen-related cell adhesion molecule 21 CEACAM21 −2.2
CCAAT/enhancer binding protein (C/EBP), δ CEBPD −1.8 (1)
CUGBP, Elav-like family member 1 CELF1 −2.4
Centrosomal protein 152kDa CEP152 −1.8
Centrosomal protein 170kDa CEP170 −2.7 (1)
Centrosomal protein 70kDa CEP70 −2.1
Complement factor I CFI −2.2
Chorionic gonadotropin, β polypeptide CGB −2.1
Chromogranin B (secretogranin 1) CHGB −2.3 (1)
C-type lectin domain family 4, member A CLEC4A −1.9
C-type lectin domain family 9, member A CLEC9A −2.0
CCR4-NOT transcription complex, subunit 3 CNOT3 −2.1
Cannabinoid receptor 1 (brain) CNR1 −2.1
Cordon-bleu WH2 repeat protein COBL −3.5 (1)
Component of oligomeric golgi complex 5 COG5 −2.3
Collagen, type XI, α 2 COL11A2 −2.0 (1)
Collagen, type V, α 1 COL5A1 −1.8 (1) MES
Carnitine palmitoyltransferase 1A (liver) CPT1A −1.9
Crystallin, μ CRYM −4.5 NL
Cold shock domain containing C2, RNA binding CSDC2 −3.0 (1)
CTAGE family, member 11, pseudogene CTAGE11P −2.2
CTS telomere maintenance complex component 1 CTC1 −2.4
Chemokine (C-X-C motif) ligand 3 CXCL3 −1.8
Dachsous 1 (Drosophila) DCHS1 −2.1
Doublecortin-like kinase 2 DCLK2 −2.6
Decorin DCN −3.0 (1)
DEAD (Asp-Glu-Ala-Asp) box polypeptide 51 DDX51 −1.9
DENN/MADD domain containing 1A DENND1A −2.5 (1)
Der1-like domain family, member 3 DERL3 −8.2
Dehydrogenase/reductase (SDR family) member 12 DHRS12 −3.7
DEXH (Asp-Glu-X-His) box polypeptide 58 DHX58 −2.3
Diaphanous homolog 3 (Drosophila) DIAPH3 −2.1 (1)
DIS3 mitotic control homolog (Saccharomyces cerevisiae) DIS3 −1.8
Dickkopf homolog 1 (Xenopus laevis) DKK1 −4.4 (4)
Dynein, axonemal, assembly factor 3 DNAAF3 −5.2
DnaJ (Hsp40) homolog, subfamily C, member 12 DNAJC12 −2.5
Estrogen receptor binding site associated, antigen, 9 EBAG9 −2.0
Extracellular matrix protein 2, female organ and adipocyte specific ECM2 −3.0
EGF-containing fibulin-like extracellular matrix protein 1 EFEMP1 −1.9 (1)
Engulfment and cell motility 1 ELMO1 −2.7 (1)
Exoribonuclease 1 ERI1 −2.1
ERI1 exoribonuclease family member 2 ERI2 −2.1
Ets variant gene 3 ETV3 −2.9 (1)
Fatty acid binding protein 7, brain FABP7 −2.0
Family with sequence similarity 153, member B FAM153B −3.7
Family with sequence similarity 5, member B FAM5B −2.6 (1)
Fanconi anemia, complementation group A FANCA −2.7
Fatty acyl CoA reductase 2 FAR2 −2.0
Fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) FGFR1 −2.9
Filamin A interacting protein 1-like FILIP1L −2.1
Hypothetical protein FLJ22184 FLJ22184 −2.8
Fibronectin leucine rich transmembrane protein 3 FLRT3 −1.9
Fibromodulin FMOD −2.0
Forkhead box A2 FOXA2 −2.0 (1)
Forkhead box R1 FOXR1 −8.3
FRAS1 related extracellular matrix protein 2 FREM2 −3.8
FRMD6 antisense RNA 1 FRMD6-AS1 −2.1
GRB2-associated binding protein 1 GAB1 −4.6 (1)
GRB2-associated binding protein 2 GAB2 −1.9 (1)
UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 13 (GalNAc-T13) GALNT13 −2.9 (1)
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UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 3 (GalNAc-T3) GALNT3 −2.8
Growth associated protein 43 GAP43 −4.2 (1)
Gap junction protein, β 6, 30kDa GJB6 −3.0
Guanine nucleotide binding protein (G protein), γ 7 GNG7 −2.5 CL
G patch domain containing 2 GPATCH2 −2.2
Glycoprotein M6B GPM6B −3.2
Glutathione peroxidase 3 (plasma) GPX3 −2.0
Glutamate receptor, ionotropic, kainate 1 GRIK1 −1.8 CL
G protein-coupled receptor kinase 5 GRK5 −1.8 (1)
Germ cell associated 1 GSG1 −2.0
H1 histone family, member N, testis-specific H1FNT −2.8
HemK methyltransferase family member 1 HEMK1 −2.6
Hairy/enhancer-of-split related with YRPW motif 2 HEY2 −2.9 (1)
Hypoxia inducible factor 3, α subunit HIF3A −2.2
Major histocompatibility complex, class II, DM β HLA-DMB −5.2
Heat shock 27kDa protein 3 HSPB3 −2.1
HUS1 checkpoint homolog b (S. pombe) HUS1B −3.4
Huntingtin interacting protein K HYPK −1.9
Islet cell autoantigen 1, 69kDa ICA1 −3.0
Interferon, α-inducible protein 27 IFI27 −2.3
Insulin-like growth factor binding protein 7 IGFBP7 −3.1 (1)
IGF-like family member 3 IGFL3 −4.8
Immunoglobulin superfamily, member 11 IGSF11 −3.2 (1)
Interleukin 8 IL8 −2.4 (1)
InaD-like (Drosophila) INADL −2.9
Insulinoma-associated 1 INSM1 −2.2
Inositol hexakisphosphate kinase 3 IP6K3 −1.8
Interferon regulatory factor 4 IRF4 −1.9
Integrin, α 6 ITGA6 −2.6
Kelch repeat and BTB (POZ) domain containing 3 KBTBD3 −2.0
Potassium channel tetramerisation domain containing 21 KCTD21 −5.2
KIAA0319-like KIAA0319L −3.4 (1)
Kruppel-like factor 4 (gut) KLF4 −2.3
Kruppel-like factor 7 (ubiquitous) KLF7 −1.8
Kelch domain containing 8A KLHDC8A −2.1 CL
Kelch-like 23 (Drosophila) KLHL23 −2.0
Kelch-like 5 (Drosophila) KLHL5 −3.8
Killer cell lectin-like receptor subfamily F, member 1 KLRF1 −4.5
Like-glycosyltransferase LARGE −5.1 (1)
Lysocardiolipin acyltransferase 1 LCLAT1 −1.8
Leptin (obesity homolog, mouse) LEP −1.9 (1)
Leprecan-like 1 LEPREL1 −3.0
Leucine-rich repeat LGI family, member 2 LGI2 −3.5
Long intergenic nonprotein coding RNA 261 LINC00261 −3.1
Long intergenic nonprotein coding RNA 282 LINC00282 −2.1
Long intergenic nonprotein coding RNA 324 LINC00324 −1.9
Long intergenic nonprotein coding RNA 478 LINC00478 −2.2
Long intergenic nonprotein coding RNA 612 LINC00612 −1.8
Long intergenic nonprotein coding RNA 623 LINC00623 −2.9
LOC100129502 −1.9
LOC100130276 −2.8
LOC100131096 −2.3
LOC100132354 −2.2
LOC255167 −2.1
LOC283710 −2.9
LOC285696 −3.7
LOC389765 −2.5
LOC441155 −2.9
LOC645355 −2.1
LOC653562 −7.3
LOC728755 −2.2
LOC730441 −3.4
Lysyl oxidase-like 3 LOXL3 −2.3
Plasticity related gene 1 LPPR4 −2.7
Leucine rich repeat containing 37, member A3 LRRC37A3 −3.1
Leucine rich repeat neuronal 1 LRRN1 −3.9 (1)
Leucine rich repeat neuronal 3 LRRN3 −3.0
Lumican LUM −2.2
Lymphocyte antigen 6 complex, locus G5C LY6G5C −2.2
Lymphocyte antigen 6 complex, locus H LY6H −3.8
Melanoma antigen family A, 11 MAGEA11 −4.2
Mal, T cell differentiation protein MAL −2.1
MANSC domain containing 1 MANSC1 −2.0
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Microtubule-associated protein 2 MAP2 −2.9 (1) PN
Mitogen-activated protein kinase kinase 6 MAP2K6 −1.8
Mitogen-activated protein kinase kinase 7 MAP2K7 −2.1 (1)
Microtubule-associated protein 6 MAP6 −2.6
Microtubule-associated protein τ MAPT −2.7 (1) PN
Membrane-associated ring finger (C3HC4) 2 MARCH2 −1.8
Microtubule associated serine/threonine kinase family member 4 MAST4 −3.4
MEF2B neighbor MEF2BNB −2.7
Malignant fibrous histiocytoma amplified sequence 1 MFHAS1 −2.8 (1)
Myocardial infarction associated transcript (nonprotein coding) MIAT −3.1
MLLT4 antisense RNA 1 (head to head) MLLT4-AS1 −1.9
Metallophosphoesterase 1 MPPE1 −2.0
Mucin 12, cell surface associated MUC12 −1.9
Myeloid-associated differentiation marker MYADM −2.1
Myosin binding protein C, slow type MYBPC1 −2.3 NL
V-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) MYCN −2.1 (1)
Myosin IE MYO1E −1.8 (1)
Myosin VC MYO5C −2.2 (1) CL
N-myc downstream regulated gene 1 NDRG1 −1.8
Nicotinamide nucleotide transhydrogenase NNT −3.3 (1)
NADPH oxidase activator 1 NOXA1 −2.3 (1)
Nuclear pore complex interacting protein family, member B15 NPIPL2 −2.6
Neuropeptide Y receptor Y5 NPY5R −2.5
Neuronal cell adhesion molecule NRCAM −2.2
Nuclear receptor binding SET domain protein 1 NSD1 −2.2
Neurotensin NTS −7.2
2′-5′-oligoadenylate synthetase 2, 69/71kDa OAS2 −1.8
Protein kinase C and casein kinase substrate in neurons 2 PACSIN2 −2.0
Peptidyl arginine deiminase, type II PADI2 −5.2
Protocadherin γ subfamily A, 5 PCDHGA5 −2.2
Protocadherin γ subfamily B, 6 PCDHGB6 −2.4
Pecanex-like 4 (Drosophila) PCNXL4 −5.6
Phosphodiesterase 8B PDE8B −6.0 (1)
Platelet-derived growth factor β polypeptide (simian sarcoma viral (v-sis) oncogene homolog) PDGFB −1.9 (1)
PDZ and LIM domain 5 PDLIM5 −2.3 (1)
Podoplanin PDPN −1.8 MES
PDZ domain containing 2 PDZD2 −1.9
PDZ domain containing RING finger 3 PDZRN3 −3.0
PHD finger protein 8 PHF8 −3.4
Phosphatidylinositol-4-phosphate 5-kinase-like 1 PIP5KL1 −2.1
Phospholipase A2, group IID PLA2G2D −2.3
Polo-like kinase 2 (Drosophila) PLK2 −1.8
Phospholipid transfer protein PLTP −3.2
Postmeiotic segregation increased 2 pseudogene 1 PMS2P1 −2.0
POM121 transmembrane nucleoporin-like 8 pseudogene POM121L8P −4.3
Protein phosphatase 2 (formerly 2A), regulatory subunit B″, α PPP2R3A −2.2
Proline rich 13 PRR13 −2.1
Protein tyrosine phosphatase type IVA, member 2 PTP4A2 −2.5
Poliovirus receptor-related 2 (herpesvirus entry mediator B) PVRL2 −4.4
Pyrroline-5-carboxylate reductase 1 PYCR1 −4.2
Pyrin and HIN domain family, member 1 PYHIN1 −3.8
RAB24, member RAS oncogene family RAB24 −1.9
RAB3A, member RAS oncogene family RAB3A −1.9
RAB3A interacting protein (rabin3) RAB3IP −3.5 (1)
Retinoic acid receptor responder (tazarotene induced) 1 RARRES1 −2.6
RNA binding motif (RNP1, RRM) protein 3 RBM3 −3.2
Retinol binding protein 7, cellular RBP7 −2.6
Regulator of calcineurin 2 RCAN2 −3.0
Replication factor C (activator 1) 5, 36.5kDa RFC5 −2.8
Raftlin family member 2 RFTN2 −2.4
Regulator of cell cycle RGCC −2.3
Rhomboid, veinlet-like 2 (Drosophila) RHBDL2 −2.3
Ρ family GTPase 2 RND2 −2.3
Ring finger protein 14 RNF14 −2.0
Ring finger protein 148 RNF148 −1.8
RNA, Ro-associated Y4 RNY4 −2.3
Ribosomal protein L37a RPL37A −2.8
Ribosomal protein S6 kinase, 90kDa, polypeptide 2 RPS6KA2 −2.4
Radical S-adenosyl methionine domain containing 2 RSAD2 −3.4
Runt-related transcription factor 3 RUNX3 −1.9
Scavenger receptor class A, member 3 SCARA3 −1.8
Secretogranin III SCG3 −7.1 PN
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Secretagogin, EF-hand calcium binding protein SCGN −2.1
Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4F SEMA4F −2.6
Serine incorporator 2 SERINC2 −3.4
Surfactant associated 1, pseudogene SFTA1P −2.8
SH2B adaptor protein 2 SH2B2 −2.7 (1)
SH3-domain kinase binding protein 1 SH3KBP1 −2.2
SH3 domain containing ring finger 2 SH3RF2 −3.1
Signal-induced proliferation-associated gene 1 SIPA1 −2.8 (1)
Signal-regulatory protein α SIRPA −4.8 (1)
Solute carrier family 16, member 4 (monocarboxylic acid transporter 5) SLC16A4 −1.8
Solute carrier family 2 (facilitated glucose transporter), member 12 SLC2A12 −2.6
Solute carrier family 30 (zinc transporter), member 1 SLC30A1 −3.6 (1)
Solute carrier family 35, member F1 SLC35F1 −4.9
Solute carrier family 38, member 8 SLC38A8 −3.0
Solute carrier family 39 (zinc transporter), member 4 SLC39A4 −2.6
Solute carrier family 5 (iodide transporter), member 8 SLC5A8 −4.4
Solute carrier family 6 (proline IMINO transporter), member 20 SLC6A20 −2.2
Solute carrier family 6 (neurotransmitter transporter, glycine), member 9 SLC6A9 −5.3 CL
Solute carrier organic anion transporter family, member 1C1 SLCO1C1 −2.4
Secretory leukocyte peptidase inhibitor SLPI −3.7
Small integral membrane protein 1 SMIM1 −2.2
Small nucleolar RNA, H/ACA box 28 SNORA28 −1.8
Small nucleolar RNA, C/D box 114-3 SNORD114-3 −1.8
Small nucleolar RNA, C/D box 14C SNORD14C −2.1
Small nucleolar RNA, C/D box 6 SNORD6 −5.9
Small nucleolar RNA, C/D box 95 SNORD95 −2.0
Sorbin and SH3 domain containing 1 SORBS1 −1.8 (1)
SRY (sex-determining region Y)-box 2 SOX2 −1.6 PN
SRY (sex-determining region Y)-box 21 SOX21 −4.3 (1)(2)
SOX2 overlapping transcript (nonprotein coding) SOX2-OT −2.0
SRY (sex-determining region Y)-box 8 SOX8 −3.7
Sperm associated antigen 1 SPAG1 −2.0
SPARC-like 1 (mast9, hevin) SPARCL1 −2.2
Spermatogenesis and centriole associated 1 SPATC1 −2.2
Speedy/RINGO cell cycle regulator family member E3 SPDYE3 −2.7
Sprouty homolog 4 (Drosophila) SPRY4 −2.0 (1)
SLIT-ROBO Ρ GTPase activating protein 1 SRGAP1 −2.1 (1)
ST8SIA6 antisense RNA 1 ST8SIA6-AS1 −1.9
STAU2 antisense RNA 1 STAU2-AS1 −3.2
Synapse differentiation inducing 1 SYNDIG1 −2.2
TBC1 domain family, member 17 TBC1D17 −2.5
Transducin (β)-like 3 TBL3 −1.8
Tyrosyl-DNA phosphodiesterase 1 TDP1 −1.9
Trefoil factor 3 (intestinal) TFF3 −3.0
Transmembrane protein 100 TMEM100 −1.9
Transmembrane protein 106A TMEM106A −1.9 (1)
Transmembrane protein 156 TMEM156 −3.1
Transmembrane protein 161B TMEM161B −2.2
Transmembrane protein 164 TMEM164 −3.0
Transmembrane protein 178A TMEM178A −1.9
Tumor protein p63 TP63 −5.4
Tumor protein D52 TPD52 −3.8 (1)
Tripartite motif-containing 24 TRIM24 −1.8 (1)
tRNA methyltransferase 44 homolog (Saccharomyces cerevisiae) TRMT44 −2.8
Transient receptor potential cation channel, subfamily M, member 3 TRPM3 −2.8 (1)
Tetraspanin 14 TSPAN14 −2.1
Testis specific protein, Y-linked 1 TSPY1 −2.4
Tweety homolog 1 (Drosophila) TTYH1 −3.1
Taxilin γ 2, pseudogene TXLNG2P −2.0
UDP glucuronosyltransferase 2 family, polypeptide B11 UGT2B11 −4.6
Urotensin 2 UTS2 −2.3
Vaccinia related kinase 3 VRK3 −4.9
WD repeat domain 49 WDR49 −2.0 (1)
WD repeat domain 74 WDR74 −3.0
WD repeat domain 86 WDR86 −2.4
WD repeat domain 89 WDR89 −3.3
X antigen family, member 1D XAGE1D −6.3
Zinc finger and BTB domain containing 40 ZBTB40 −7.8
Zinc finger with KRAB and SCAN domains 5 ZKSCAN5 −3.2
Zinc finger protein 182 ZNF182 −5.5
Zinc finger protein 519 ZNF519 −2.3
Zinc finger protein 555 ZNF555 −1.9
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Zinc finger protein 608 ZNF608 −2.0 (1)
Zinc finger protein 678 ZNF678 −2.3
Zinc finger protein 717 ZNF717 −2.3
Zinc finger protein 761 ZNF761 −1.8
Zinc finger protein 880 ZNF880 −2.4
Zinc finger protein 890, pseudogene ZNF890P −2.0
Zinc finger and SCAN domain containing 12 ZSCAN12 −1.8
Zinc finger and SCAN domain containing 16 ZSCAN16 −2.4
Zinc finger, X-linked, duplicated B ZXDB −1.8
Aminoadipate aminotransferase AADAT 5.0 (1)
Acyl-Coenzyme A dehydrogenase family, member 8 ACAD8 1.8
Actin, α 2, smooth muscle, aorta ACTA2 2.2
ADAM metallopeptidase domain 28 ADAM28 2.3 (1)
ADAM metallopeptidase with thrombospondin type 1 motif, 18 ADAMTS18 1.8
Adenylate cyclase 9 ADCY9 3.3
Alcohol dehydrogenase 6 (class V) ADH6 2.3
AF4/FMR2 family, member 3 AFF3 2.7 (1)
1-acylglycerol-3-phosphate O-acyltransferase 3 AGPAT3 2.5
Aldo-keto reductase family 1 member 15 (ALD2) AKR1B15 1.9
Aminolevulinate, δ-, synthase 2 (sideroblastic/hypochromic anemia) ALAS2 2.9
Angiopoietin-like 3 ANGPTL3 2.3
Angiopoietin-like 4 ANGPTL4 1.9
Ankyrin 1, erythrocytic ANK1 2.4
Anoctamin 2 ANO2 2.1
Annexin A8-like 2 ANXA8L2 2.5
Adaptor-related protein complex 1 associated regulatory protein AP1AR 3.3
Amyloid β (A4) precursor protein-binding, family B, member 2 (Fe65-like) APBB2 8.0
Adenomatosis polyposis coli down-regulated 1-like APCDD1L 1.9 (1)
Apolipoprotein E APOE 1.9
Ρ GDP dissociation inhibitor (GDI) β ARHGDIB 2.2
ADP-ribosylation factor-like 9 ARL9 1.8
Armadillo repeat containing 8 ARMC8 1.9
Achaete-scute complex homolog 2 (Drosophila) ASCL2 2.8
Aspartic peptidase, retroviral-like 1 ASPRV1 2.1
Argininosuccinate synthetase 1 ASS1 2.7
ATPase, class V, type 10B ATP10B 2.4
Attractin ATRN 2.1
BAI1-associated protein 2-like 1 BAIAP2L1 2.1 (1)
Biglycan BGN 2.5
Βine-homocysteine methyltransferase 2 BHMT2 1.9
BR serine/threonine kinase 2 BRSK2 2.1
Bone marrow stromal cell antigen 1 BST1 2.0
Biotinidase BTD 2.4
Blood vessel epicardial substance BVES 2.1
Chromosome 11 open reading frame 31 C11orf31 4.5
Chromosome 17 open reading frame 99 C17orf99 3.2
Chromosome 1 open reading frame 115 C1orf115 2.1
Chromosome 1 open reading frame 141 C1orf141 3.4
Chromosome 1 open reading frame 170 C1orf170 1.9
Chromosome 20 open reading frame 201 C20orf201 2.3
Chromosome 21 open reading frame 49 C21orf49 2.0
Chromosome 21 open reading frame 67 C21orf67 2.2
Chromosome 2 open reading frame 40 C2orf40 5.2
Chromosome 2 open reading frame 81 C2orf81 2.7
Chromosome 3 open reading frame 52 C3orf52 2.2
Chromosome 8 open reading frame 46 C8orf46 4.7
Chromosome 9 open reading frame 106 C9orf106 2.0
Calcium binding protein 7 CABP7 3.9
Calcium channel, voltage-dependent, L type, α 1C subunit CACNA1C 2.3 (1)
Cancer antigen 1 CAGE1 3.5
Caspase 6, apoptosis-related cysteine peptidase CASP6 2.8
Coiled-coil domain containing 163, pseudogene CCDC163P 2.3
Coiled-coil domain containing 42B CCDC42B 1.8
Coiled-coil domain containing 57 CCDC57 3.2 (1)
Chemokine (C-C motif) receptor 2 CCR2 2.1
CD163 molecule-like 1 CD163L1 2.2
CD302 molecule CD302 2.4
CDC14 cell division cycle 14 homolog A (Saccharomyces cerevisiae) CDC14A 5.0
CDC42 effector protein (Ρ GTPase binding) 5 CDC42EP5 2.1
Cadherin 15, M-cadherin (myotubule) CDH15 6.0 (1)
CDP-diacylglycerol–inositol 3-phosphatidyltransferase (phosphatidylinositol synthase) CDIPT 1.9
Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) CDKN2D 2.2
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Cdon homolog (mouse) CDON 1.9
Chromodomain protein, Y-linked, 1 CDY1 2.0
Carcinoembryonic antigen-related cell adhesion molecule 2, pseudogene CEACAM22P 3.5
Centrosomal protein 112kDa (CCDC46) CEP112 2.2
Centrosomal protein 85kDa-like CEP85L 6.7
Cripto, FRL-1, cryptic family 1 CFC1 3.6
Chorionic gonadotropin, β polypeptide 1 CGB1 1.9
ChaC, cation transport regulator homolog 2 (E. coli) CHAC2 2.7
Carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 CHST15 2.9
C-type lectin domain family 4, member C CLEC4C 4.7
Clavesin 2 CLVS2 4.8
CKLF-like MARVEL transmembrane domain containing 4 CMTM4 2.7
Cannabinoid receptor interacting protein 1 CNRIP1 3.0
Collagen, type I, α 1 COL1A1 2.6 MES
Collagen, type I, α 2 COL1A2 2.9 (1) MES
Collagen, type IV, α 6 COL4A6 2.5 (1)
Collagen, type V, α 3 COL5A3 3.9
Collagen, type VI, α 2 COL6A2 2.8
Collagen, type IX, α 2 COL9A2 1.8
COMM domain containing 8 COMMD8 2.1
Coronin, actin binding protein, 1A CORO1A 2.0
Carboxypeptidase B1 (tissue) CPB1 3.3
Cytokine receptor-like factor 2 CRLF2 2.8
Crystallin, γ S CRYGS 2.9
Chondrosarcoma associated gene 1 CSAG1 2.9
Connective tissue growth factor CTGF 2.5
Cathepsin H CTSH 5.2
Cytokine-like 1 CYTL1 2.5
D-2-hydroxyglutarate dehydrogenase D2HGDH 2.6
DAB2 interacting protein DAB2IP 3.0
Death associated protein-like 1 DAPL1 2.2
Deleted in azoospermia 4 DAZ4 3.1
DCN1, defective in cullin neddylation 1, domain containing 2 (Saccharomyces cerevisiae) DCUN1D2 2.5
Defensin, β 106A DEFB106A 5.9
Defensin, β 128 DEFB128 2.7
DEP domain containing 7 DEPDC7 2.1
DiGeorge syndrome critical region gene 5 (noncoding) DGCR5 4.0
Disrupted in renal carcinoma 3 DIRC3 2.0
DKFZP434L187 protein DKFZP434L187 1.9
Δ-like 2 homolog (Drosophila) DLK2 2.9
Dmx-like 1 DMXL1 2.0
DNA (cytosine-5-)-methyltransferase 3 β DNMT3B 2.5
Deoxynucleotidyltransferase, terminal, interacting protein 2 DNTTIP2 3.2
Dipeptidyl-peptidase 8 DPP8 5.4
Dermatopontin DPT 2.0
Dpy-19-like 2 pseudogene 2 (C. elegans) DPY19L2P2 3.1
Dorsal inhibitory axon guidance protein DRAXIN 2.1
Dopamine receptor D2 DRD2 3.5
Dystonin DST 1.9
E2F transcription factor 8 E2F8 1.9
Epstein-Barr virus induced gene 3 EBI3 2.1
Ephrin-B1 EFNB1 2.4
ELK4, ETS-domain protein (SRF accessory protein 1) ELK4 2.6
EP400 N-terminal like EP400NL 2.2
Envoplakin EVPL 2.3
Coagulation factor VIII, procoagulant component (hemophilia A) F8 6.1
Fatty acid binding protein 4, adipocyte FABP4 2.0
Family with sequence similarity 110, member D FAM110D 2.5
Family with sequence similarity 159, member B FAM159B 2.7
Family with sequence similarity 174, member A FAM174A 2.1
Family with sequence similarity 179, member A FAM179A 2.5
Family with sequence similarity 196, member A FAM196A 1.8
Family with sequence similarity 27-like FAM27L 2.1
Family with sequence similarity 65, member C FAM65C 4.1
Family with sequence similarity 71, member C FAM71C 5.8
Family with sequence similarity 72, member A FAM72A 1.8
Fibulin 1 FBLN1 2.6 (1)
FBXO22 antisense RNA 1 FBXO22-AS1 3.2
Fc receptor-like 3 FCRL3 2.0
FLJ31945 6.2
FLJ37786 2.6
FLJ45248 1.8
Filamin C, γ (actin binding protein 280) FLNC 2.4
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Fibronectin type III domain containing 5 FNDC5 2.6
Folate receptor 1 (adult) FOLR1 2.0
Forkhead box K2 FOXK2 5.2 (1)
Forkhead box protein O6 FOXO6 4.8
Forkhead box S1 FOXS1 3.2
Fraser syndrome 1 FRAS1 2.6
FSHD region gene 2 family, member C FRG2C 2.6
Frizzled-related protein FRZB 2.4
FtsJ methyltransferase domain containing 2 FTSJD2 2.5
FXYD domain containing ion transport regulator 5 FXYD5 1.9
Glucose-6-phosphatase, catalytic subunit G6PC 2.7
Γ-aminobutyric acid (GABA) receptor, ρ 1 GABRR1 5.2
G antigen 1 GAGE1 6.9
GRINL1A combined protein GCOM1 3.2
Glutamine-fructose-6-phosphate transaminase 2 GFPT2 2.6
Glycoprotein, α-galactosyltransferase 1 (GGTA1), noncoding RNA. GGTA1P 2.6
GTPase, IMAP family member 4 GIMAP4 2.1
Gap junction protein, β 2, 26kDa GJB2 2.0
GLI pathogenesis-related 1 (glioma) GLIPR1 3.0
Guanine nucleotide binding protein (G protein), α 14 GNA14 1.8
Golgin A6 family, member C GOLGA6C 3.5
Golgin A6 family-like 9 GOLGA6L9 2.1
Golgin A8 family, member I GOLGA8I 3.5
Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 GPIHBP1 2.0
Glycoprotein M6A GPM6A 2.2 PN
G protein-coupled receptor 128 GPR128 2.3
G protein-coupled receptor 18 GPR18 1.9
Growth factor receptor-bound protein 14 GRB14 1.9
GREB1 protein GREB1 2.2
Glutamate receptor, ionotropic, N-methyl D-aspartate 2B GRIN2B 3.0
General transcription factor IIH, polypeptide 2, 44kDa GTF2H2 3.8
Glycogenin 2 GYG2 2.0
Hyaluronan synthase 3 HAS3 3.4
HAUS augmin-like complex, subunit 5 HAUS5 2.2
Hemoglobin, α 1 HBA1 1.9
Hyperpolarization activated cyclic nucleotide-gated potassium channel 1 HCN1 2.3
Histone deacetylase 7 HDAC7 1.9
High density lipoprotein binding protein (vigilin) HDLBP 6.8 (1)
Hairy and enhancer of split 2 (Drosophila) HES2 2.7
Histone cluster 1, H2ag HIST1H2AG 3.0
Major histocompatibility complex, class I, A HLA-A 3.4
Major histocompatibility complex, class II, DR α HLA-DRA 2.2
H2.0-like homeobox HLX 3.6
Histamine N-methyltransferase HNMT 2.0 (1)
Homeobox B4 HOXB4 2.2
Harakiri, BCL2 interacting protein (contains only BH3 domain) HRK 4.2
Heat shock transcription factor, Y-linked 1 HSFY1 5.1
Heat shock protein 90kDa α (cytosolic), class B member 4 (pseudogene) HSP90AB4P 1.8
Histatin 3 HTN3 2.4
Hydrocephalus inducing homolog (mouse) HYDIN 3.5
Insulin-like growth factor binding protein 3 IGFBP3 2.3 (1)
Interleukin 15 receptor, α IL15RA 2.1 MES
Interleukin 17 receptor B IL17RB 4.4
Interleukin 1 receptor, type II IL1R2 2.1 (1)
Interleukin 1 receptor accessory protein IL1RAP 1.9 (1)
Interleukin 2 receptor, β IL2RB 2.4
Interleukin 5 (colony-stimulating factor, eosinophil) IL5 2.9
Inhibitor of growth family, member 1 ING1 1.9
Inversin INVS 2.4
Interferon regulatory factor 5 IRF5 2.3
Interferon regulatory factor 6 IRF6 1.8
KAT8 regulatory NSL complex subunit 1-like KANSL1L 2.2
Potassium inwardly-rectifying channel, subfamily J, member 4 KCNJ4 2.6
Potassium large conductance calcium-activated channel, subfamily M β member 3 KCNMB3 4.6
Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 KCNS3 1.9 (1)
Potassium channel, subfamily V, member 2 KCNV2 2.5
KIAA1033 KIAA1033 1.8
KIAA1211-like KIAA1211L 2.2
Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 KIR3DL1 2.5
Klotho KL 2.6
Kallikrein-related peptidase 14 KLK14 4.6
Laminin, β 3 LAMB3 2.3 (1)
(continued on next page)
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TABLE W1. (continued)
CSC
Description Symbol Fold Change
(Log2)
Sox2 Target
(Ref)
Subclass
Signature
Leukocyte cell derived chemotaxin 1 LECT1 1.8
LIM homeobox 1 LHX1 8.0 (1)
LIM homeobox 6 LHX6 2.2
Long intergenic nonprotein coding RNA 265 LINC00265 2.2
Long intergenic nonprotein coding RNA 426 LINC00426 1.9
Long intergenic nonprotein coding RNA 427 LINC00427 2.4
Long intergenic nonprotein coding RNA 545 LINC00545 1.8
Lines homolog (Drosophila) LINS 2.0
LIM homeobox transcription factor 1, α LMX1A 3.2 (1)
LOC100128239 3.2
LOC100128292 2.1
LOC100131551 1.9
LOC100132418 1.8
LOC100506060 1.8
LOC148696 1.9
LOC286083 2.0
LOC402160 3.6
LOC440895 2.3
LOC644248 2.4
LOC645177 3.1
LOC728724 2.6
LOC93432 2.2
Leucine-rich repeats and guanylate kinase domain containing LRGUK 2.7
Low density lipoprotein-related protein 12 LRP12 3.3 (1)
Leucine rich repeat containing 32 LRRC32 4.5 (1)
LY6/PLAUR domain containing 6B LYPD6B 8.0
Mab-21-like 1 (C. elegans) MAB21L1 3.1 CL
MAFF interacting protein (pseudogene) MAFIP 2.8
Melanoma antigen family A, 1 (directs expression of antigen MZ2-E) MAGEA1 2.7 (1)
Melanoma antigen family A, 3 MAGEA3 2.4 (1)
Melanoma antigen family B, 1 MAGEB1 2.1
Melanoma antigen family C, 2 MAGEC2 1.9 (1)
Mago-nashi homolog B (Drosophila) MAGOHB 4.3
Mannosidase, β A, lysosomal-like MANBAL 2.2 (1)
Microtubule-associated protein 1 light chain 3 γ MAP1LC3C 3.1
Membrane-associated ring finger (C3HC4) 1 MARCH1 3.3
MARVEL domain containing 1 MARVELD1 2.4
Myoglobin MB 3.7
MCF.2 cell line derived transforming sequence MCF2 7.3
Minichromosome maintenance domain containing 2 MCMDC2 2.0
Mucolipin 3 MCOLN3 2.2
Methyltransferase like 2B METTL2B 2.3
Microfibrillar-associated protein 4 MFAP4 7.1
MGC72080 2.5 CL
Matrix Gla protein MGP 2.0
MER1 repeat containing imprinted transcript 1 MIMT1 2.6
MKL/myocardin-like 2 MKL2 2.0
Myeloid/lymphoid or mixed-lineage leukemia 3 MLL3 2.1 (1)
Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 10 MLLT10 3.3 (1)
Motilin MLN 3.0
Membrane metallo-endopeptidase MME 3.8
Matrix metallopeptidase 13 (collagenase 3) MMP13 3.1 (1)
Matrix metallopeptidase 23A (pseudogene) MMP23A 2.2
Membrane protein, palmitoylated 4 (MAGUK p55 subfamily member 4) MPP4 2.8
Mitochondrial ribosomal protein L3 MRPL3 1.9
Mitochondrial ribosomal protein S12 MRPS12 3.0
Membrane-spanning 4-domains, subfamily A, member 2 (Fc fragment of IgE, high affinity I,
receptor for; β polypeptide)
MS4A2 2.2
Mucin 19, oligomeric MUC19 5.0
MAX interactor 1 MXI1 5.0
V-myc myelocytomatosis viral oncogene homolog 1, lung carcinoma derived (avian) MYCL1 2.0 (1)
Myosin, light chain 10, regulatory MYL10 1.8
Myosin IB MYO1B 4.6
Myosin IC MYO1C 2.3
NLR family, apoptosis inhibitory protein NAIP 2.4
Neuroblastoma breakpoint family, member 15 NBPF15 2.8
Neurocalcin δ NCALD 1.8 PN
Neutrophil cytosolic factor 1, (chronic granulomatous disease, autosomal 1) NCF1 2.6
Nonprotein coding RNA 185 NCRNA00185 1.8
NEBL antisense RNA 1 NEBL-AS1 1.8
NEL-like 1 (chicken) NELL1 2.1 (1)
Nucleolar complex associated 4 homolog (Saccharomyces cerevisiae) NOC4L 2.1
NADPH oxidase organizer 1 NOXO1 2.2 (1)
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TABLE W1. (continued)
CSC
Description Symbol Fold Change
(Log2)
Sox2 Target
(Ref)
Subclass
Signature
Neuropeptide S NPS 2.2 (1)
Neuronal pentraxin II NPTX2 3.1 (1)
Neurexin 2 NRXN2 2.1 PN
Neurotensin receptor 1 (high affinity) NTSR1 2.8
Optic atrophy 3 (autosomal recessive, with chorea and spastic paraplegia) OPA3 2.7
Olfactory receptor, family 11, subfamily A, member 1 OR11A1 2.1
Olfactory receptor, family 2, subfamily A, member 9 pseudogene OR2A9P 4.6
Olfactory receptor, family 51, subfamily E, member 2 OR51E2 3.6
OTU domain containing 1 OTUD1 2.1
Purinergic receptor P2X, ligand-gated ion channel, 3 P2RX3 3.5
P antigen family, member 5 (prostate associated) PAGE5 1.9
Paralemmin 3 PALM3 4.7
Par-3 partitioning defective 3 homolog (C. elegans) PARD3 3.0
Protocadherin 11 X-linked PCDH11X 3.5
Protocadherin α 12 PCDHA12 5.5
Protocadherin γ subfamily B, 7 PCDHGB7 2.9
Phosducin-like 3 pseudogene 4 PDCL3P4 2.2
Platelet-derived growth factor receptor, β polypeptide PDGFRB 2.8
Pyridoxal-dependent decarboxylase domain containing 2, pseudogene PDXDC2P 1.9
PDZ domain containing 1 PDZK1 3.1
Platelet/endothelial cell adhesion molecule (CD31 antigen) PECAM1 1.9
Pepsinogen 3, group I (pepsinogen A) PGA3 3.5
Placental growth factor, vascular endothelial growth factor-related protein PGF 2.7
Pleckstrin homology-like domain, family A, member 3 PHLDA3 2.0
Phosphatidylinositol 4-kinase type 2 β PI4K2B 2.3
Phospholipase A2, group IIC PLA2G2C 2.5
Plasminogen activator, urokinase PLAU 1.8 MES
Plasminogen activator, urokinase receptor PLAUR 2.5 MES
Phospholipase C-like 2 PLCL2 2.4
Pleckstrin homology domain containing, family G (with ΡGef domain) member 3 PLEKHG3 2.3
Premelanosome protein PMEL 2.6
POM121 transmembrane nucleoporin-like 1, pseudogene POM121L1P 2.6
Proopiomelanocortin (adrenocorticotropin/ β-lipotropin/ α-melanocyte stimulating hormone/
β-melanocyte stimulating hormone/ β-endorphin)
POMC 2.0
Peptidylprolyl isomerase E (cyclophilin E) PPIE 1.9
Protein phosphatase 1, regulatory (inhibitor) subunit 9B PPP1R9B 2.0
PR domain containing 1, with ZNF domain PRDM1 4.4
Protein kinase C, ε PRKCE 2.2 (1)
Proline rich 5 (renal) PRR5 4.2 (1)
Prostaglandin D2 synthase 21kDa (brain) PTGDS 5.5
Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) PTGS1 5.2
Protein tyrosine phosphatase, receptor type, E PTPRE 1.8
Protein tyrosine phosphatase, receptor type, O PTPRO 1.9 (1)
Pyridine nucleotide-disulphide oxidoreductase domain 2 PYROXD2 1.8
RAB20, member RAS oncogene family RAB20 2.2 (1)
RAB30, member RAS oncogene family RAB30 1.8
Retinoic acid early transcript 1G RAET1G 6.2
RAN guanine nucleotide release factor RANGRF 1.9
Rap guanine nucleotide exchange factor (GEF) 5 RAPGEF5 2.2
Retinoic acid receptor, α RARA 2.2
RAS protein activator like 2 RASAL2 2.7
RASD family, member 2 RASD2 2.6 (1)
Ras association (RalGDS/AF-6) domain family 6 RASSF6 4.1
Retinoblastoma binding protein 6 RBBP6 2.4
RCC1 domain containing 1 RCCD1 2.0
RELT tumor necrosis factor receptor RELT 3.0
Regulatory factor X, 7 RFX7 1.8
Rhomboid 5 homolog 2 (Drosophila) RHBDF2 2.1
Ripply1 homolog (zebrafish) RIPPLY1 2.2
Ring finger protein 186 RNF186 2.1
Retinitis pigmentosa 1 (autosomal dominant) RP1 2.4 (1)
Reprimo-like RPRML 2.4
Ras-related associated with diabetes RRAD 2.2
Runt-related transcription factor 1; translocated to, 1 (cyclin D-related) RUNX1T1 2.1 (1)
Sterile α motif domain containing 14 SAMD14 2.3
SET binding factor 1 pseudogene 1 SBF1P1 2.9
Small Cajal body-specific RNA 13 SCARNA13 2.3
Small Cajal body-specific RNA 9-like SCARNA9L 2.6
Secretogranin V (7B2 protein) SCG5 2.6
Sodium channel, voltage-gated, type I, β SCN1B 2.9
Sidekick homolog 2 (chicken) SDK2 2.2 (1)
Selectin E (endothelial adhesion molecule 1) SELE 1.9
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TABLE W1. (continued)
CSC
Description Symbol Fold Change
(Log2)
Sox2 Target
(Ref)
Subclass
Signature
Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D SEMA3D 3.2 (1)
Serpin peptidase inhibitor, clade A (α-1 antiproteinase, antitrypsin), member 3 SERPINA3 4.9
Serpin peptidase inhibitor, clade I (neuroserpin), member 1 SERPINI1 4.0 NL
SH3 and PX domains 2A SH3PXD2A 6.2 (1)
Src homology 2 domain containing E SHE 3.2
Src homology 2 domain containing F SHF 2.1
SIX homeobox 4 SIX4 1.8
Solute carrier family 16, member 10 (aromatic amino acid transporter) SLC16A10 2.5 (1)
Solute carrier family 16, member 14 (monocarboxylic acid transporter 14) SLC16A14 1.9
Solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), member 7 SLC17A7 2.5
Solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 SLC25A15 2.3
Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 24 SLC25A24 7.4
Solute carrier family 25, member 52 SLC25A52 2.5
Solute carrier family 26, member 4 SLC26A4 2.5
Solute carrier family 27 (fatty acid transporter), member 4 SLC27A4 3.5
Solute carrier family 39 (zinc transporter), member 12 SLC39A12 3.0
Solute carrier family 39 (zinc transporter), member 3 SLC39A3 1.8
Solute carrier family 39 (zinc transporter), member 8 SLC39A8 2.0
Solute carrier family 45, member 3 SLC45A3 2.2
Solute carrier family 46, member 2 SLC46A2 2.3
Solute carrier family 5 (sodium/glucose cotransporter), member 2 SLC5A2 5.7
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 2 SMARCC2 2.5
Small integral membrane protein 8 SMIM8 2.6
Snail homolog 2 (Drosophila) SNAI2 2.0
Small nuclear RNA activating complex, polypeptide 3, 50kDa SNAPC3 3.9
Stannin SNN 2.0
Small nucleolar RNA, H/ACA box 72 SNORA72 2.6
Small nucleolar RNA, C/D box 101 SNORD101 1.9
Small nucleolar RNA, C/D box 113-6 SNORD113-6 3.4
Sorting nexin family member 21 SNX21 2.2
Sosondowah ankyrin repeat domain family member A SOWAHA 3.2
SRY (sex-determining region Y)-box 18 SOX18 2.2
SP100 nuclear antigen SP100 2.2 MES
Sperm associated antigen 16 SPAG16 2.0
SPATA31 subfamily D, member 5, pseudogene SPATA31D5P 2.3
Speedy homolog A (Drosophila) SPDYA 2.5
Speedy/RINGO cell cycle regulator family member E6 SPDYE6 3.3
Sphingosine kinase 1 SPHK1 1.8
Spondin 1, extracellular matrix protein SPON1 2.0
Steroidogenic acute regulatory protein STAR 3.5
Serine/threonine kinase 16 STK16 4.3
Serine/threonine kinase 17b STK17B 2.1 (1)
Suppressor of G2 allele of SKP1 (Saccharomyces cerevisiae) pseudogene 3 SUGT1P3 2.4
Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3 SULT1A3 2.1
Sad1 and UNC84 domain containing 3 SUN3 5.2
Sushi domain containing 2 SUSD2 2.9
Supervillin SVIL 6.8 (1)
Synaptonemal complex central element protein 3 SYCE3 2.0
Synaptotagmin III SYT3 2.0
Transgelin TAGLN 2.6
T cell acute lymphocytic leukemia 2 TAL2 4.3
TBC1 domain family, member 26 TBC1D26 2.7
Transducin (β)-like 1Y-linked TBL1Y 3.9
T cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3 TCIRG1 1.9 MES
Testis development related 1 (nonprotein coding) TDRG1 3.9
TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal) TEK 2.0 (1)
Testis-specific kinase 2 TESK2 7.3
Tet methylcytosine dioxygenase 3 TET3 5.4
THAP domain containing 4 THAP4 2.5
Tight junction protein 3 TJP3 3.2
Transmembrane 4 L six family member 19 TM4SF19 2.0
Transmembrane channel-like 4 TMC4 4.9
Transmembrane protein with EGF-like and two follistatin-like domains 2 TMEFF2 2.3 (1)
Transmembrane protein 107 TMEM107 1.8
Transmembrane protein 110 TMEM110 2.2
Transmembrane protein 120B TMEM120B 2.0
Transmembrane protein 191B TMEM191B 2.7
Transmembrane protein 65 TMEM65 1.8
Thioredoxin-related transmembrane protein 1 TMX1 5.5
Tumor necrosis factor, α-induced protein 2 TNFAIP2 1.9
Tumor necrosis factor, α-induced protein 8 TNFAIP8 1.9 MES
Tumor necrosis factor receptor superfamily, member 18 TNFRSF18 2.5
Tumor necrosis factor (ligand) superfamily, member 12 TNFSF12 2.8
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CSC
Description Symbol Fold Change
(Log2)
Sox2 Target
(Ref)
Subclass
Signature
TNNI3 interacting kinase TNNI3K 2.7
Topoisomerase (DNA) I pseudogene 1 TOP1P1 2.9
TOX high-mobility group box family member 2 TOX2 2.6
Tumor protein p53 regulated apoptosis inducing protein 1 TP53AIP1 2.1
Trafficking protein particle complex 6B TRAPPC6B 1.9
TRNA aspartic acid methyltransferase 1 TRDMT1 2.4
Tripartite motif-containing 51E, pseudogene TRIM51EP 2.7
Transient receptor potential cation channel, subfamily M, member 1 TRPM1 3.5
Testis-specific transcript, Y-linked 5 TTTY5 2.4
Tubulin, α 8 TUBA8 2.3
Tubulin, β pseudogene 5 TUBBP5 4.4
Urocortin 2 UCN2 3.1
Vestigial like 2 (Drosophila) VGLL2 1.9
Vitelline membrane outer layer 1 homolog (chicken) VMO1 2.0 (1)
Vanin 2 VNN2 4.8
WASH and IL9R antisense RNA 1 WASIR1 4.0
WD repeat domain 63 WDR63 4.1
WD repeat domain 87 WDR87 1.8
WAP four-disulfide core domain 2 WFDC2 2.9
YME1-like 1 (Saccharomyces cerevisiae) YME1L1 2.2
YPLR6490 2.4
Zinc finger, CCHC domain containing 12 ZCCHC12 2.1
Zinc finger, FYVE domain containing 27 ZFYVE27 2.4
ZMIZ1 antisense RNA 1 ZMIZ1-AS1 2.0
Zinc finger, MYND-type containing 15 ZMYND15 2.7
Zinc finger protein 138 ZNF138 2.9
Zinc finger protein 48 ZNF48 2.2
Zinc finger protein 493 ZNF493 2.3
Zinc finger protein 570 ZNF570 3.8
Zinc finger protein 607 ZNF607 2.0
Zinc finger protein 793 ZNF793 3.6
Zinc finger protein 815, pseudogene ZNF815P 2.9
Zinc finger protein 847, pseudogene ZNF847P 2.7
Zona pellucida-like domain containing 1 ZPLD1 2.1
Bold, genes commonly regulated in SCS and CSC; italic, genes regulated in oposite directions in SDC and CSC.
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Table W2. Genes Highly Correlated with Sox2 mRNA Expression in the TCGA Data.
Gene ID Correlation In Vitro Sox2 Knockdown DEG Sox2 Target (Ref) Verhaak Subclass
ABCA3 Positive
ARNT2 Positive SDC
ASTN1 Positive CSC
B3GAT1 Positive SDC (1)
BAALC Positive SDC
BAI2 Positive
BCAN Positive PN
C1orf61 Positive SDC (1) PN
C3orf39 Positive
CHST10 Positive SDC
CKB Positive SDC PN
CLIP3 Positive
CTNND2 Positive
DBI Positive
DCLK2 Positive
DDR1 Positive
DENND5A (RAB61P1) Positive (1)
DNAJB5 Positive
DTX1 Positive
EBF4 Positive
FAM181B (MGC33846) Positive (1)
FEZ1 Positive SDC (1)
FXYD6 Positive (1) PN
GDF1 Positive
GNA11 Positive
GPM6B Positive SDC, CSC
GPR56 Positive SDC CL
HEPN1 Positive
ID4 Positive
JAKMIP2 Positive
KEAP1 Positive CL
LRIG1 Positive (1)
METRN Positive SDC
MLC1 Positive CL
MT3 Positive
NFIX Positive
NLRP1 Positive
NR2F1 Positive (1)
OLIG1 Positive
OSBPL6 Positive SDC (1)
PCDHGA1 Positive
POU3F2 Positive
PTPRZ1 Positive (1)
RGMA Positive
SHC3 Positive
SLC1A3 Positive SDC (1)
SOX2 Positive SDC,CSC (1) PN
SOX21 Positive SDC,CSC (1) (2)
TBCB Positive
TCEA2 Positive
TTYH1 Positive SDC, CSC PN
TUBA4A Positive
TUBB2A Positive
TUBB2B Positive SDC
TUBB6 Positive
TUBB8 Positive
ZBTB47 Positive
ANXA3 Negative SDC NL
ATF1 Negative
B3GNT2 Negative (1)
C4orf32 Negative (1)
C6orf211 Negative
FEM1B Negative
ITGA4 Negative MES
MOB1A Negative
MST4 Negative
NUDT15 Negative
PCYOX1 Negative
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TABLE W2. (continued)
Gene ID Correlation In Vitro Sox2 Knockdown DEG Sox2 Target (Ref) Verhaak Subclass
PTPN2 Negative
RALB Negative (1)
STT3B Negative
TBC1D8B Negative
THOC7 Negative
TMF1 Negative
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